Dossier zur Nutzenbewertung gemäß § 35a SGB V

Evinacumab (Evkeeza®)

Ultragenyx Germany GmbH

Separater Anhang 4-G

Behandlung von erwachsenen und jugendlichen Patienten ab einem Alter von 12 Jahren mit homozygoter familiärer Hypercholesterinämie (HoFH)

Medizinischer Nutzen und medizinischer Zusatznutzen, Patientengruppen mit therapeutisch bedeutsamem Zusatznutzen

Stand: 05.01.2024

Inhalt

Table 14.4.15 Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Demographic Characteristics ITT Population

Demographic characteristics	Placebo IV Q4W (N=22)	Evinacumab 15 mg/kg IV Q4W (N=43)	Total (N=65)
Gender			
Male			
n	11	19	30
Mean (SD)	244.5 (133.86)	222.0 (121.90)	230.3 (124.60)
Median	209.0	198.0	203.0
Q1 : Q3	117.0 : 348.0	148.0 : 266.0	148.0 : 319.0
Min : Max	110 : 503	46 : 580	46 : 580
Female			
n	11	24	35
Mean (SD)	248.5 (178.01)	289.2 (201.41)	276.4 (192.69)
Median	195.0	216.5	202.0
Q1 : Q3	140.0 : 324.0	152.0 : 388.5	149.0 : 363.0
Min : Max	39 : 605	71 : 907	39 : 907
Age			
<65			
n	22	35	57
Mean (SD)	246.5 (153.71)	288.4 (177.24)	272.2 (168.39)
Median	198.5	222.0	211.0
Q1 : Q3	140.0 : 324.0	172.0 : 363.0	156.0 : 347.0
Min : Max	39 : 605	46 : 907	39 : 907

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim1/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_dem.sas (lei.yu 18NOV2019 09:27 SAS Linux 9.4)

Table 14.4.15 Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Demographic Characteristics
ITT Population

Demographic characteristics	Placebo IV Q4W (N=22)	Evinacumab 15 mg/kg IV Q4W (N=43)	Total (N=65)
Age			
>=65			
n	0	8	8
Mean (SD)		133.1 (57.73)	133.1 (57.73)
Median		109.0	109.0
Q1 : Q3		87.5 : 194.5	87.5 : 194.5
Min : Max		71 : 212	71 : 212
Race			
White			
n	17	31	48
Mean (SD)	246.4 (155.90)	269.1 (194.20)	261.1 (180.18)
Median	195.0	198.0	197.5
Q1 : Q3	150.0 : 245.0	126.0 : 363.0	144.0 : 336.0
Min : Max	110 : 605	46 : 907	46 : 907
Black or African American			
n	0	2	2
Mean (SD)		258.5 (246.78)	258.5 (246.78)
Median		258.5	258.5
Q1 : Q3		84.0 : 433.0	84.0 : 433.0
Min : Max		84 : 433	84 : 433

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim1/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_dem.sas (lei.yu 18NOV2019 09:27 SAS Linux 9.4)

Table 14.4.15 Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Demographic Characteristics
ITT Population

Demographic characteristics	Placebo IV Q4W (N=22)	Evinacumab 15 mg/kg IV Q4W (N=43)	Total (N=65)
Race			
Asian			
n	4	6	10
Mean (SD)	299.0 (133.16)	191.0 (23.11)	234.2 (96.53)
Median	336.0	194.5	209.5
Q1 : Q3	216.0 : 382.0	179.0 : 211.0	179.0 : 324.0
Min : Max	108 : 416	155 : 212	108 : 416
Not Reported			
n	0	2	2
Mean (SD)		339.5 (10.61)	339.5 (10.61)
Median		339.5	339.5
Q1 : Q3		332.0 : 347.0	332.0 : 347.0
Min : Max		332 : 347	332 : 347
Other			
n	1	2	3
Mean (SD)	39.0 (.)	237.0 (91.92)	171.0 (131.50)
Median	39.0	237.0	172.0
Q1 : Q3	39.0 : 39.0	172.0 : 302.0	39.0 : 302.0
Min : Max	39 : 39	172 : 302	39 : 302

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim1/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_dem.sas (lei.yu 18NOV2019 09:27 SAS Linux 9.4)

Table 14.4.15 Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Demographic Characteristics
ITT Population

Demographic characteristics	Placebo IV Q4W (N=22)	Evinacumab 15 mg/kg IV Q4W (N=43)	Total (N=65)
Ethnicity			
Hispanic or Latino			
n	1	1	2
Mean (SD)	156.0 (.)	179.0 (.)	167.5 (16.26)
Median	156.0	179.0	167.5
Q1 : Q3	156.0 : 156.0	179.0 : 179.0	156.0 : 179.0
Min : Max	156 : 156	179 : 179	156 : 179
Not Hispanic or Latino			
n	20	38	58
Mean (SD)	247.5 (159.39)	252.6 (180.49)	250.8 (172.10)
Median	198.5	197.5	197.5
Q1 : Q3	128.5 : 336.0	148.0 : 333.0	140.0 : 333.0
Min : Max	39 : 605	46 : 907	39 : 907
Not Reported			
n	1	4	5
Mean (SD)	319.0 (.)	345.5 (41.46)	340.2 (37.81)
Median	319.0	339.5	332.0
Q1 : Q3	319.0 : 319.0	317.0 : 374.0	319.0 : 347.0
Min : Max	319 : 319	302 : 401	302 : 401

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim1/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_dem.sas (lei.yu 18NOV2019 09:27 SAS Linux 9.4)

Table 14.4.15 Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Demographic Characteristics
ITT Population

Demographic characteristics	Placebo IV Q4W (N=22)	Evinacumab 15 mg/kg IV Q4W (N=43)	Total (N=65)
Region			
Japan			
n	4	6	10
Mean (SD)	299.0 (133.16)	191.0 (23.11)	234.2 (96.53)
Median	336.0	194.5	209.5
Q1 : Q3	216.0 : 382.0	179.0 : 211.0	179.0 : 324.0
Min : Max	108 : 416	155 : 212	108 : 416
Rest of World			
n	18	37	55
Mean (SD)	234.9 (158.95)	270.6 (183.56)	258.9 (175.22)
Median	187.0	211.0	198.0
Q1 : Q3	140.0 : 245.0	148.0 : 347.0	140.0 : 339.0
Min : Max	39 : 605	46 : 907	39 : 907

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim1/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_dem.sas (lei.yu 18NOV2019 09:27 SAS Linux 9.4)

Table 14.4.16 Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Other Baseline Characteristics
ITT Population

	Placebo IV Q4W (N=22)	Evinacumab 15 mg/kg IV Q4W (N=43)	Total (N=65)
Baseline apheresis status per IVRS			
Yes			
n	8	14	22
Mean (SD)	245.9 (119.67)	256.6 (99.79)	252.7 (104.72)
Median	257.0	211.5	211.5
Q1 : Q3	128.5 : 336.0	179.0 : 347.0	179.0 : 347.0
Min : Max	108 : 416	108 : 414	108 : 416
No			
n	14	29	43
Mean (SD)	246.9 (174.51)	260.9 (199.89)	256.3 (190.02)
Median	190.5	197.0	197.0
Q1 : Q3	150.0 : 245.0	126.0 : 333.0	126.0 : 333.0
Min : Max	39 : 605	46 : 907	39 : 907

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim1/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_othbl.sas (lei.yu 18NOV2019 09:27 SAS Linux 9.4)

Protocol: R1500-CL-1629

Table 14.4.17 Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Baseline Calculated LDL-C
ITT Population

	Placebo IV Q4W (N=22)	Evinacumab 15 mg/kg IV Q4W (N=43)	Total (N=65)
Baseline Calculated LDL-C			
<130 mg/dL			
n	5	9	14
Mean (SD)	97.8 (33.07)	92.9 (25.50)	94.6 (27.25)
Median	110.0	91.0	108.0
Q1 : Q3	108.0 : 115.0	81.0 : 110.0	81.0 : 115.0
Min : Max	39 : 117	46 : 126	39 : 126
>=130 mg/dL			
n	17	34	51
Mean (SD)	290.3 (147.61)	303.6 (167.62)	299.2 (159.86)
Median	232.0	230.5	232.0
Q1 : Q3	179.0 : 348.0	180.0 : 363.0	179.0 : 363.0
Min : Max	140 : 605	148 : 907	140 : 907

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim1/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_ldlbl.sas (lei.yu 18NOV2019 09:27 SAS Linux 9.4)

Protocol: R1500-CL-1629

Table 14.4.18 Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to HoFH Genotyping
ITT Population

	Placebo IV Q4W (N=22)	Evinacumab 15 mg/kg IV Q4W (N=43)	Total (N=65)
HoFH Genotyping			
Homozygous			
n	8	22	30
Mean (SD)	226.5 (106.65)	320.4 (192.51)	295.4 (177.10)
Median	238.5	284.0	255.5
Q1 : Q3	152.5 : 321.5	180.0 : 363.0	179.0 : 347.0
Min : Max	39 : 348	110 : 907	39 : 907
Compound Heterozygous			
n	8	12	20
Mean (SD)	346.1 (193.12)	256.7 (127.12)	292.5 (158.48)
Median	312.5	204.5	210.0
Q1 : Q3	190.5 : 525.0	173.0 : 367.0	179.0 : 415.0
Min : Max	108 : 605	81 : 505	81 : 605
Double Heterozygous			
n	1	2	3
Mean (SD)	115.0 (.)	96.0 (16.97)	102.3 (16.26)
Median	115.0	96.0	108.0
Q1 : Q3	115.0 : 115.0	84.0 : 108.0	84.0 : 115.0
Min : Max	115 : 115	84 : 108	84 : 115

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim1/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_hofh.sas (lei.yu 18NOV2019 09:27 SAS Linux 9.4)

Table 14.4.19 Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Receptor-negative Mutation in Both LDLR Alleles
ITT Population

	Placebo IV Q4W (N=22)	Evinacumab 15 mg/kg IV Q4W (N=43)	Total (N=65)
Receptor-negative Mutation in Both LDLR Alleles			
Receptor Negative/Negative			
n	6	4	10
Mean (SD)	264.3 (143.38)	357.5 (56.16)	301.6 (121.60)
Median	321.5	347.5	328.0
Q1 : Q3	140.0 : 348.0	317.0 : 398.0	302.0 : 363.0
Min : Max	39 : 416	302 : 433	39 : 433
Non Receptor Negative/Negative			
n	15	38	53
Mean (SD)	239.5 (167.06)	250.4 (179.72)	247.3 (174.70)
Median	179.0	189.0	181.0
Q1 : Q3	117.0 : 232.0	148.0 : 333.0	148.0 : 325.0
Min : Max	108 : 605	46 : 907	46 : 907

Note: Receptor-negative defined as a mutation resulting in termination codons, splice site mutations, frame shifts and large insertion/deletions.
There are two patients with receptor negative/negative in LDLRAP1, so they are not included for this table.

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim1/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_recep.sas (lei.yu 18NOV2019 09:27 SAS Linux 9.4)

Protocol: R1500-CL-1629

Table 14.4.20 Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Receptor-negative Mutation in Both LDLR or
LDLRAP1 Alleles
ITT Population

	Placebo IV Q4W (N=22)	Evinacumab 15 mg/kg IV Q4W (N=43)	Total (N=65)
Receptor-negative Mutation in Both LDLR or LDLRAP1 Alleles			
Receptor Negative/Negative			
n	7	5	12
Mean (SD)	261.6 (131.09)	328.4 (81.24)	289.4 (113.83)
Median	319.0	332.0	321.5
Q1 : Q3	140.0 : 348.0	302.0 : 363.0	228.5 : 355.5
Min : Max	39 : 416	212 : 433	39 : 433
Non Receptor Negative/Negative			
n	15	38	53
Mean (SD)	239.5 (167.06)	250.4 (179.72)	247.3 (174.70)
Median	179.0	189.0	181.0
Q1 : Q3	117.0 : 232.0	148.0 : 333.0	148.0 : 325.0
Min : Max	108 : 605	46 : 907	46 : 907

Note: Receptor-negative defined as a mutation resulting in termination codons, splice site mutations, frame shifts and large insertion/deletions.

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim1/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_recap.sas (lei.yu 18NOV2019 09:27 SAS Linux 9.4)

Table 14.4.21 Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Null/Null Mutation in Both LDLR Alleles
ITT Population

	Placebo IV Q4W (N=22)	Evinacumab 15 mg/kg IV Q4W (N=43)	Total (N=65)
Null/Null Mutation in Both LDLR Alleles			
Null/Null			
n	5	15	20
Mean (SD)	310.6 (185.22)	316.3 (159.16)	314.9 (160.92)
Median	319.0	266.0	284.0
Q1 : Q3	165.0 : 324.0	197.0 : 401.0	189.0 : 382.0
Min : Max	140 : 605	148 : 662	140 : 662
Not Null/Null			
n	16	28	44
Mean (SD)	226.6 (148.78)	229.1 (174.21)	228.2 (163.65)
Median	187.0	179.0	179.0
Q1 : Q3	116.0 : 290.0	114.5 : 329.0	116.0 : 329.0
Min : Max	39 : 547	46 : 907	39 : 907

There is one patient with null/null mutation in both LDLRAP1, so this patient is not included in this table.

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim1/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_nul.sas (lei.yu 18NOV2019 09:27 SAS Linux 9.4)

Table 14.4.22 Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Null/Null Mutation in Both LDLR or LDLRAP1
Alleles
ITT Population

	Placebo IV Q4W (N=22)	Evinacumab 15 mg/kg IV Q4W (N=43)	Total (N=65)
Null/Null Mutation in Both LDLR or LDLRAP1 Alleles			
Null/Null			
n	6	15	21
Mean (SD)	299.7 (167.82)	316.3 (159.16)	311.5 (157.58)
Median	282.0	266.0	266.0
Q1 : Q3	165.0 : 324.0	197.0 : 401.0	197.0 : 363.0
Min : Max	140 : 605	148 : 662	140 : 662
Not Null/Null			
n	16	28	44
Mean (SD)	226.6 (148.78)	229.1 (174.21)	228.2 (163.65)
Median	187.0	179.0	179.0
Q1 : Q3	116.0 : 290.0	114.5 : 329.0	116.0 : 329.0
Min : Max	39 : 547	46 : 907	39 : 907

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim1/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_nulap.sas (lei.yu 18NOV2019 09:27 SAS Linux 9.4)

Table 14.4.23 Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Patients with Statin at Baseline
ITT Population

	Placebo IV Q4W (N=22)	Evinacumab 15 mg/kg IV Q4W (N=43)	Total (N=65)
Statin at Baseline			
Yes			
n	20	41	61
Mean (SD)	248.1 (157.03)	264.8 (174.39)	259.3 (167.77)
Median	198.5	208.0	202.0
Q1 : Q3	145.0 : 321.5	155.0 : 339.0	150.0 : 333.0
Min : Max	39 : 605	46 : 907	39 : 907
No			
n	2	2	4
Mean (SD)	231.5 (164.76)	151.0 (84.85)	191.3 (116.65)
Median	231.5	151.0	163.0
Q1 : Q3	115.0 : 348.0	91.0 : 211.0	103.0 : 279.5
Min : Max	115 : 348	91 : 211	91 : 348

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim1/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_stat.sas (lei.yu 18NOV2019 09:27 SAS Linux 9.4)

Table 14.4.24 Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Patients with PCSK9 Inhibitor at Baseline
ITT Population

	Placebo IV Q4W (N=22)	Evinacumab 15 mg/kg IV Q4W (N=43)	Total (N=65)
PCSK9 inhibitor at Baseline			
Yes			
n	16	34	50
Mean (SD)	230.1 (168.83)	269.0 (188.28)	256.5 (181.48)
Median	172.0	204.5	197.5
Q1 : Q3	116.0 : 238.5	149.0 : 347.0	148.0 : 339.0
Min : Max	39 : 605	46 : 907	39 : 907
No			
n	6	9	15
Mean (SD)	290.3 (102.72)	223.7 (89.40)	250.3 (97.36)
Median	321.5	208.0	212.0
Q1 : Q3	195.0 : 348.0	179.0 : 302.0	179.0 : 332.0
Min : Max	140 : 416	110 : 363	110 : 416

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim1/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_pcsk.sas (lei.yu 18NOV2019 09:27 SAS Linux 9.4)

Table 14.4.25 Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Patients with Ezetimibe at Baseline
ITT Population

	Placebo IV Q4W (N=22)	Evinacumab 15 mg/kg IV Q4W (N=43)	Total (N=65)
Ezetimibe at Baseline			
Yes			
n	16	33	49
Mean (SD)	244.1 (146.13)	267.1 (145.23)	259.6 (144.40)
Median	198.5	212.0	202.0
Q1 : Q3	145.0 : 284.5	172.0 : 347.0	165.0 : 339.0
Min : Max	108 : 605	81 : 662	81 : 662
No			
n	6	10	16
Mean (SD)	253.2 (187.33)	234.4 (250.61)	241.4 (222.42)
Median	237.5	181.5	182.0
Q1 : Q3	110.0 : 348.0	84.0 : 211.0	97.0 : 322.0
Min : Max	39 : 547	46 : 907	39 : 907

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim1/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_eze.sas (lei.yu 18NOV2019 09:27 SAS Linux 9.4)

Protocol: R1500-CL-1629

Table 14.4.26 Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Patients with Lomitapide at Baseline
ITT Population

	Placebo IV Q4W (N=22)	Evinacumab 15 mg/kg IV Q4W (N=43)	Total (N=65)
Lomitapide at Baseline			
Yes			
n	3	11	14
Mean (SD)	199.7 (33.56)	191.5 (65.34)	193.3 (58.90)
Median	202.0	181.0	189.5
Q1 : Q3	165.0 : 232.0	149.0 : 211.0	155.0 : 211.0
Min : Max	165 : 232	110 : 363	110 : 363
No			
n	19	32	51
Mean (SD)	253.9 (164.36)	282.8 (191.55)	272.1 (180.76)
Median	195.0	230.5	211.0
Q1 : Q3	117.0 : 348.0	146.5 : 374.0	126.0 : 348.0
Min : Max	39 : 605	46 : 907	39 : 907

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim1/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_lom.sas (lei.yu 18NOV2019 09:27 SAS Linux 9.4)

Table 14.9.3.42 Calculated LDL-C Over Time (On-treatment estimand) in Conventional Units - Raw Data Description: Subgroup Analysis According to Null/Null Mutation in Both
LDLR or LDLRAP1 Alleles
Open-label Safety Analysis Set - OLTP

	Null/Null			Not Null/Null		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mg/dL)	DB Placebo IV Q4W (N=6)	Q4W (N=15)	Total (N=21)	DB Placebo IV Q4W (N=14)	Q4W (N=29)	Total (N=43)
Baseline						
Value						
n	6	15	21	14	29	43
Mean (SD)	299.7 (167.82)	316.3 (159.16)	311.5 (157.58)	208.8 (130.08)	226.6 (171.61)	220.8 (157.93)
Median	282.0	266.0	266.0	187.0	179.0	179.0
Q1 : Q3	165 : 324	197 : 401	197 : 363	115 : 232	119 : 325	115 : 325
Min : Max	140 : 605	148 : 662	140 : 662	39 : 503	46 : 907	39 : 907
Week 28						
Value						
n	6	14	20	13	27	40
Mean (SD)	150.5 (92.97)	170.1 (85.50)	164.3 (85.80)	109.5 (65.86)	101.8 (69.90)	104.3 (67.86)
Median	115.5	171.0	156.0	82.0	91.0	86.0
Q1 : Q3	103 : 202	107 : 212	105 : 209	60 : 155	56 : 114	58 : 133
Min : Max	54 : 313	41 : 325	41 : 325	34 : 229	28 : 313	28 : 313
Change from Baseline						
n	6	14	20	13	27	40
Mean (SD)	-149.2 (96.00)	-155.8 (124.21)	-153.8 (113.98)	-103.8 (93.13)	-121.1 (130.84)	-115.5 (118.95)
Median	-156.5	-145.5	-145.5	-89.0	-76.0	-78.5
Q1 : Q3	-195 : -62	-192 : -81	-194 : -72	-150 : -48	-170 : -53	-165 : -51
Min : Max	-292 : -33	-456 : 34	-456 : 34	-293 : 45	-594 : 39	-594 : 45

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8000_ldlcv_sum_nul.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.42 Calculated LDL-C Over Time (On-treatment estimand) in Conventional Units - Raw Data Description: Subgroup Analysis According to Null/Null Mutation in Both LDLR or LDLRAP1 Alleles

Open-label Safety Analysis Set - OLTP

| | Null/Null | | | Not Null/Null | | |
| | | DB Evinacumab 15 mg/kg IV | | | DB Evinacumab 15 mg/kg IV | |
Calculated LDL-C (mg/dL)	DB Placebo IV Q4W (N=6)	Q4W (N=15)	Total (N=21)	DB Placebo IV Q4W (N=14)	Q4W (N=29)	Total (N=43)
Week 28						
Percent Change from Baseline						
n	6	14	20	13	27	40
Mean (SD)	-47.69 (19.400)	-44.59 (25.896)	-45.52 (23.664)	-41.47 (31.020)	-45.01 (34.038)	-43.86 (32.730)
Median	-42.96	-46.11	-46.11	-49.72	-52.94	-51.33
Q1 : Q3	-61.1 : -37.6	-68.9 : -35.6	-65.0 : -36.6	-58.3 : -34.2	-65.5 : -39.4	-65.0 : -37.2
Min : Max	-78.0 : -23.6	-73.3 : 17.3	-78.0 : 17.3	-83.2 : 40.9	-92.4 : 56.5	-92.4 : 56.5
Week 32						
Value						
n	6	15	21	13	27	40
Mean (SD)	121.7 (57.49)	162.3 (80.04)	150.7 (75.26)	101.0 (54.56)	103.7 (71.25)	102.9 (65.59)
Median	113.0	143.0	135.0	79.0	82.0	80.5
Q1 : Q3	101 : 152	99 : 223	101 : 195	65 : 144	55 : 127	59 : 136
Min : Max	39 : 212	61 : 314	39 : 314	33 : 198	18 : 319	18 : 319

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8000_ldlcv_sum_nul.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.42 Calculated LDL-C Over Time (On-treatment estimand) in Conventional Units - Raw Data Description: Subgroup Analysis According to Null/Null Mutation in Both LDLR or LDLRAP1 Alleles
Open-label Safety Analysis Set - OLTP

	Null/Null			Not Null/Null		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mg/dL)	DB Placebo IV Q4W (N=6)	Q4W (N=15)	Total (N=21)	DB Placebo IV Q4W (N=14)	Q4W (N=29)	Total (N=43)
Week 32						
Change from Baseline						
n	6	15	21	13	27	40
Mean (SD)	-178.0 (152.02)	-153.9 (133.95)	-160.8 (135.87)	-107.8 (103.83)	-124.0 (131.63)	-118.8 (122.18)
Median	-157.0	-120.0	-120.0	-101.0	-97.0	-99.0
Q1 : Q3	-206 : -56	-268 : -49	-214 : -56	-150 : -52	-175 : -48	-165 : -50
Min : Max	-453 : -39	-467 : 28	-467 : 28	-323 : 65	-588 : 65	-588 : 65
Percent Change from Baseline						
n	6	15	21	13	27	40
Mean (SD)	-53.11 (24.026)	-43.34 (27.527)	-46.13 (26.367)	-42.71 (33.783)	-42.57 (48.660)	-42.61 (43.928)
Median	-48.95	-55.30	-55.30	-50.00	-54.19	-53.51
Q1 : Q3	-74.9 : -33.9	-64.5 : -16.8	-64.5 : -27.9	-59.8 : -43.1	-69.0 : -30.8	-65.5 : -41.8
Min : Max	-84.1 : -27.9	-77.1 : 14.2	-84.1 : 14.2	-71.1 : 59.1	-91.7 : 141.3	-91.7 : 141.3

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8000_ldlcv_sum_nul.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.42 Calculated LDL-C Over Time (On-treatment estimand) in Conventional Units - Raw Data Description: Subgroup Analysis According to Null/Null Mutation in Both
LDLR or LDLRAP1 Alleles
Open-label Safety Analysis Set - OLTP

	Null/Null			Not Null/Null		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mg/dL)	DB Placebo IV Q4W (N=6)	Q4W (N=15)	Total (N=21)	DB Placebo IV Q4W (N=14)	Q4W (N=29)	Total (N=43)
Week 36						
Value						
n	6	14	20	12	28	40
Mean (SD)	123.5 (69.70)	175.1 (74.30)	159.7 (75.13)	103.9 (68.40)	104.7 (72.72)	104.5 (70.57)
Median	102.5	168.5	158.5	77.5	93.0	86.0
Q1 : Q3	92 : 168	103 : 217	100 : 210	63 : 135	57 : 116	57 : 116
Min : Max	38 : 238	79 : 324	38 : 324	33 : 266	38 : 347	33 : 347
Change from Baseline						
n	6	14	20	12	28	40
Mean (SD)	-176.2 (118.47)	-148.6 (136.41)	-156.9 (128.81)	-106.0 (91.38)	-117.9 (124.15)	-114.3 (114.27)
Median	-181.5	-92.0	-128.0	-85.5	-84.5	-84.5
Q1 : Q3	-219 : -73	-239 : -58	-229 : -63	-156 : -44	-157 : -43	-156 : -43
Min : Max	-367 : -35	-487 : 34	-487 : 34	-340 : -6	-560 : 62	-560 : 62
Percent Change from Baseline						
n	6	14	20	12	28	40
Mean (SD)	-55.20 (20.739)	-40.04 (24.396)	-44.59 (23.899)	-45.56 (19.460)	-41.38 (44.660)	-42.63 (38.619)
Median	-54.40	-41.66	-44.50	-47.59	-48.08	-47.62
Q1 : Q3	-68.7 : -44.2	-58.7 : -30.9	-60.1 : -32.0	-62.3 : -33.4	-65.6 : -40.8	-64.3 : -38.4
Min : Max	-84.5 : -25.0	-73.6 : 17.3	-84.5 : 17.3	-69.8 : -10.0	-85.4 : 134.8	-85.4 : 134.8

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8000_ldlcv_sum_nul.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.42 Calculated LDL-C Over Time (On-treatment estimand) in Conventional Units - Raw Data Description: Subgroup Analysis According to Null/Null Mutation in Both LDLR or LDLRAP1 Alleles

Open-label Safety Analysis Set - OLTP

	Null/Null			Not Null/Null		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mg/dL)	DB Placebo IV Q4W (N=6)	Q4W (N=15)	Total (N=21)	DB Placebo IV Q4W (N=14)	Q4W (N=29)	Total (N=43)
Week 40						
Value						
n	6	15	21	13	26	39
Mean (SD)	142.0 (94.99)	171.5 (95.08)	163.0 (93.65)	92.4 (48.93)	106.6 (71.90)	101.8 (64.83)
Median	106.5	125.0	117.0	85.0	97.5	93.0
Q1 : Q3	92 : 232	102 : 251	102 : 232	60 : 106	55 : 119	55 : 119
Min : Max	32 : 283	72 : 408	32 : 408	21 : 176	32 : 343	21 : 343
Change from Baseline						
n	6	15	21	13	26	39
Mean (SD)	-157.7 (110.34)	-144.8 (150.25)	-148.5 (137.41)	-116.4 (103.14)	-124.0 (127.70)	-121.4 (118.75)
Median	-152.5	-112.0	-112.0	-110.0	-91.0	-103.0
Q1 : Q3	-215 : -73	-254 : -40	-215 : -73	-169 : -29	-184 : -64	-172 : -49
Min : Max	-322 : -31	-505 : 142	-505 : 142	-354 : -4	-564 : 69	-564 : 69
Percent Change from Baseline						
n	6	15	21	13	26	39
Mean (SD)	-50.39 (24.301)	-40.46 (31.742)	-43.30 (29.564)	-48.91 (23.630)	-40.91 (49.520)	-43.58 (42.476)
Median	-48.73	-48.22	-48.22	-56.41	-56.86	-56.41
Q1 : Q3	-67.4 : -28.4	-61.3 : -22.3	-61.3 : -28.4	-66.5 : -36.7	-68.2 : -37.4	-67.7 : -36.7
Min : Max	-86.9 : -22.1	-76.3 : 53.4	-86.9 : 53.4	-83.7 : -3.6	-82.9 : 150.0	-83.7 : 150.0

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8000_ldlcv_sum_nul.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

VV-RIM-00102077-1.0 Approved - 24 May 2020 GMT-5:00

Protocol: R1500-CL-1629

Table 14.9.3.42 Calculated LDL-C Over Time (On-treatment estimand) in Conventional Units - Raw Data Description: Subgroup Analysis According to Null/Null Mutation in Both LDLR or LDLRAP1 Alleles

Open-label Safety Analysis Set - OLTP

	Null/Null			Not Null/Null		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mg/dL)	DB Placebo IV Q4W (N=6)	Q4W (N=15)	Total (N=21)	DB Placebo IV Q4W (N=14)	Q4W (N=29)	Total (N=43)
Week 44						
Value						
n	6	14	20	13	25	38
Mean (SD)	116.7 (60.94)	195.9 (136.85)	172.1 (123.19)	82.5 (49.59)	109.4 (73.06)	100.2 (66.53)
Median	103.5	179.5	164.5	68.0	89.0	78.0
Q1 : Q3	58 : 181	107 : 209	100 : 199	52 : 99	64 : 125	57 : 125
Min : Max	55 : 199	66 : 622	55 : 622	24 : 172	8 : 308	8 : 308
Change from Baseline						
n	6	14	20	13	25	38
Mean (SD)	-183.0 (132.57)	-121.4 (176.39)	-139.9 (163.56)	-126.2 (96.32)	-116.0 (141.39)	-119.5 (126.49)
Median	-157.5	-83.0	-108.5	-114.0	-79.0	-99.0
Q1 : Q3	-210 : -107	-269 : -46	-240 : -50	-171 : -67	-175 : -62	-175 : -62
Min : Max	-424 : -42	-486 : 259	-486 : 259	-356 : -11	-599 : 177	-599 : 177
Percent Change from Baseline						
n	6	14	20	13	25	38
Mean (SD)	-57.82 (18.960)	-33.20 (37.765)	-40.58 (34.705)	-56.07 (19.076)	-33.19 (76.343)	-41.01 (63.400)
Median	-65.34	-45.96	-51.58	-58.46	-52.10	-58.14
Q1 : Q3	-70.1 : -38.6	-53.9 : -19.2	-65.3 : -30.6	-69.8 : -51.3	-65.9 : -38.5	-66.3 : -38.9
Min : Max	-77.6 : -30.0	-73.4 : 71.3	-77.6 : 71.3	-79.5 : -10.0	-90.5 : 249.3	-90.5 : 249.3

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8000_ldlcv_sum_nul.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.42 Calculated LDL-C Over Time (On-treatment estimand) in Conventional Units - Raw Data Description: Subgroup Analysis According to Null/Null Mutation in Both LDLR or LDLRAP1 Alleles
Open-label Safety Analysis Set - OLTP

	Null/Null			Not Null/Null		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mg/dL)	DB Placebo IV Q4W (N=6)	Q4W (N=15)	Total (N=21)	DB Placebo IV Q4W (N=14)	Q4W (N=29)	Total (N=43)
Week 48						
Value						
n	5	14	19	11	28	39
Mean (SD)	142.4 (111.33)	157.1 (72.36)	153.2 (81.12)	91.5 (61.49)	107.2 (78.87)	102.8 (73.93)
Median	90.0	133.5	125.0	78.0	94.0	89.0
Q1 : Q3	61 : 258	108 : 192	90 : 240	51 : 173	50 : 122	51 : 123
Min : Max	36 : 267	55 : 308	36 : 308	14 : 186	25 : 391	14 : 391
Change from Baseline						
n	5	14	19	11	28	39
Mean (SD)	-153.4 (120.35)	-160.2 (138.66)	-158.4 (130.82)	-141.2 (95.34)	-115.3 (116.12)	-122.6 (110.05)
Median	-104.0	-102.5	-104.0	-118.0	-85.5	-91.0
Q1 : Q3	-209 : -66	-265 : -55	-265 : -55	-217 : -57	-172 : -51	-185 : -57
Min : Max	-338 : -50	-494 : -28	-494 : -28	-326 : -21	-516 : 77	-516 : 77
Percent Change from Baseline						
n	5	14	19	11	28	39
Mean (SD)	-52.06 (25.058)	-45.45 (21.805)	-47.19 (22.178)	-57.50 (22.242)	-41.33 (46.849)	-45.89 (41.762)
Median	-55.87	-52.54	-52.61	-54.36	-51.94	-54.36
Q1 : Q3	-63.0 : -35.7	-63.1 : -27.0	-63.1 : -27.0	-65.9 : -46.6	-66.8 : -37.8	-65.9 : -38.6
Min : Max	-85.3 : -20.4	-74.6 : -13.5	-85.3 : -13.5	-93.5 : -19.1	-83.3 : 117.4	-93.5 : 117.4

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8000_ldlcv_sum_nul.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.42 Calculated LDL-C Over Time (On-treatment estimand) in Conventional Units - Raw Data Description: Subgroup Analysis According to Null/Null Mutation in Both
LDLR or LDLRAP1 Alleles
Open-label Safety Analysis Set - OLTP

	Null/Null			Not Null/Null		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mg/dL)	DB Placebo IV Q4W (N=6)	Q4W (N=15)	Total (N=21)	DB Placebo IV Q4W (N=14)	Q4W (N=29)	Total (N=43)
FU - W4						
Value						
n	0	2	2	0	2	2
Mean (SD)		123.0 (67.88)	123.0 (67.88)		151.5 (85.56)	151.5 (85.56)
Median		123.0	123.0		151.5	151.5
Q1 : Q3		75 : 171	75 : 171		91 : 212	91 : 212
Min : Max		75 : 171	75 : 171		91 : 212	91 : 212
Change from Baseline						
n	0	2	2	0	2	2
Mean (SD)		-73.0 (89.10)	-73.0 (89.10)		-124.0 (4.24)	-124.0 (4.24)
Median		-73.0	-73.0		-124.0	-124.0
Q1 : Q3		-136 : -10	-136 : -10		-127 : -121	-127 : -121
Min : Max		-136 : -10	-136 : -10		-127 : -121	-127 : -121
Percent Change from Baseline						
n	0	2	2	0	2	2
Mean (SD)		-34.99 (41.670)	-34.99 (41.670)		-47.27 (13.868)	-47.27 (13.868)
Median		-34.99	-34.99		-47.27	-47.27
Q1 : Q3		-64.5 : -5.5	-64.5 : -5.5		-57.1 : -37.5	-57.1 : -37.5
Min : Max		-64.5 : -5.5	-64.5 : -5.5		-57.1 : -37.5	-57.1 : -37.5

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8000_ldlcv_sum_nul.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.43 Calculated LDL-C Over Time (On-treatment estimand) in SI Units - Raw Data Description: Subgroup Analysis According to Null/Null Mutation in Both LDLR or LDLRAP1 Alleles
Open-label Safety Analysis Set - OLTP

	Null/Null			Not Null/Null		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mmol/L)	DB Placebo IV Q4W (N=6)	Q4W (N=15)	Total (N=21)	DB Placebo IV Q4W (N=14)	Q4W (N=29)	Total (N=43)
Baseline						
Value						
n	6	15	21	14	29	43
Mean (SD)	7.762 (4.3460)	8.191 (4.1230)	8.069 (4.0818)	5.408 (3.3681)	5.868 (4.4441)	5.718 (4.0897)
Median	7.305	6.890	6.890	4.845	4.640	4.640
Q1 : Q3	4.27 : 8.39	5.10 : 10.39	5.10 : 9.40	2.98 : 6.01	3.08 : 8.42	2.98 : 8.42
Min : Max	3.63 : 15.67	3.83 : 17.15	3.63 : 17.15	1.01 : 13.03	1.19 : 23.49	1.01 : 23.49
Week 28						
Value						
n	6	14	20	13	27	40
Mean (SD)	3.898 (2.4087)	4.408 (2.2139)	4.255 (2.2221)	2.835 (1.7057)	2.636 (1.8106)	2.700 (1.7577)
Median	2.990	4.430	4.045	2.120	2.360	2.225
Q1 : Q3	2.67 : 5.23	2.77 : 5.49	2.72 : 5.42	1.55 : 4.01	1.45 : 2.95	1.50 : 3.45
Min : Max	1.40 : 8.11	1.06 : 8.42	1.06 : 8.42	0.88 : 5.93	0.73 : 8.11	0.73 : 8.11
Change from Baseline						
n	6	14	20	13	27	40
Mean (SD)	-3.863 (2.4856)	-4.034 (3.2176)	-3.983 (2.9523)	-2.690 (2.4113)	-3.138 (3.3883)	-2.993 (3.0803)
Median	-4.055	-3.765	-3.765	-2.310	-1.970	-2.030
Q1 : Q3	-5.05 : -1.60	-4.97 : -2.09	-5.01 : -1.85	-3.89 : -1.25	-4.40 : -1.37	-4.28 : -1.31
Min : Max	-7.56 : -0.86	-11.81 : 0.88	-11.81 : 0.88	-7.59 : 1.16	-15.38 : 1.01	-15.38 : 1.16

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8000_ldlsi_sum_nul.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.43 Calculated LDL-C Over Time (On-treatment estimand) in SI Units - Raw Data Description: Subgroup Analysis According to Null/Null Mutation in Both LDLR or LDLRAP1 Alleles

Open-label Safety Analysis Set - OLTP

	Null/Null			Not Null/Null		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mmol/L)	DB Placebo IV Q4W (N=6)	Q4W (N=15)	Total (N=21)	DB Placebo IV Q4W (N=14)	Q4W (N=29)	Total (N=43)
Week 28						
Percent Change from Baseline						
n	6	14	20	13	27	40
Mean (SD)	-47.69 (19.380)	-44.57 (25.892)	-45.51 (23.658)	-41.50 (30.960)	-45.02 (34.012)	-43.88 (32.695)
Median	-42.95	-46.08	-46.08	-49.78	-52.92	-51.35
Q1 : Q3	-61.1 : -37.5	-68.9 : -35.6	-65.0 : -36.5	-58.3 : -34.2	-65.6 : -39.5	-65.0 : -37.1
Min : Max	-78.0 : -23.7	-73.3 : 17.3	-78.0 : 17.3	-83.2 : 40.7	-92.4 : 56.3	-92.4 : 56.3
Week 32						
Value						
n	6	15	21	13	27	40
Mean (SD)	3.152 (1.4889)	4.205 (2.0730)	3.904 (1.9493)	2.615 (1.4138)	2.687 (1.8459)	2.664 (1.6994)
Median	2.925	3.700	3.500	2.050	2.120	2.085
Q1 : Q3	2.62 : 3.94	2.56 : 5.78	2.62 : 5.05	1.68 : 3.73	1.42 : 3.29	1.52 : 3.51
Min : Max	1.01 : 5.49	1.58 : 8.13	1.01 : 8.13	0.85 : 5.13	0.47 : 8.26	0.47 : 8.26

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8000_ldlsi_sum_nul.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.43 Calculated LDL-C Over Time (On-treatment estimand) in SI Units - Raw Data Description: Subgroup Analysis According to Null/Null Mutation in Both LDLR or LDLRAP1 Alleles
Open-label Safety Analysis Set - OLTP

	Null/Null			Not Null/Null		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mmol/L)	DB Placebo IV Q4W (N=6)	Q4W (N=15)	Total (N=21)	DB Placebo IV Q4W (N=14)	Q4W (N=29)	Total (N=43)
Week 32						
Change from Baseline						
n	6	15	21	13	27	40
Mean (SD)	-4.610 (3.9365)	-3.987 (3.4702)	-4.165 (3.5195)	-2.792 (2.6874)	-3.213 (3.4091)	-3.076 (3.1638)
Median	-4.065	-3.100	-3.100	-2.610	-2.520	-2.565
Q1 : Q3	-5.34 : -1.45	-6.94 : -1.27	-5.54 : -1.45	-3.88 : -1.35	-4.53 : -1.24	-4.26 : -1.30
Min : Max	-11.73 : -1.01	-12.10 : 0.73	-12.10 : 0.73	-8.37 : 1.68	-15.23 : 1.68	-15.23 : 1.68
Percent Change from Baseline						
n	6	15	21	13	27	40
Mean (SD)	-53.10 (24.030)	-43.33 (27.524)	-46.12 (26.365)	-42.78 (33.715)	-42.58 (48.637)	-42.64 (43.895)
Median	-48.94	-55.24	-55.24	-49.90	-54.31	-53.57
Q1 : Q3	-74.9 : -34.0	-64.4 : -16.9	-64.4 : -27.8	-59.9 : -43.1	-69.3 : -30.7	-65.5 : -41.8
Min : Max	-84.1 : -27.8	-77.1 : 14.3	-84.1 : 14.3	-71.0 : 58.9	-91.7 : 141.2	-91.7 : 141.2

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8000_ldlsi_sum_nul.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.43 Calculated LDL-C Over Time (On-treatment estimand) in SI Units - Raw Data Description: Subgroup Analysis According to Null/Null Mutation in Both LDLR or LDLRAP1 Alleles
Open-label Safety Analysis Set - OLTP

	Null/Null			Not Null/Null		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mmol/L)	DB Placebo IV Q4W (N=6)	Q4W (N=15)	Total (N=21)	DB Placebo IV Q4W (N=14)	Q4W (N=29)	Total (N=43)
Week 36						
Value						
n	6	14	20	12	28	40
Mean (SD)	3.197 (1.8048)	4.536 (1.9239)	4.135 (1.9459)	2.691 (1.7725)	2.710 (1.8844)	2.705 (1.8288)
Median	2.655	4.365	4.105	2.010	2.410	2.225
Q1 : Q3	2.38 : 4.35	2.67 : 5.62	2.59 : 5.43	1.63 : 3.50	1.46 : 2.99	1.48 : 2.99
Min : Max	0.98 : 6.16	2.05 : 8.39	0.98 : 8.39	0.85 : 6.89	0.98 : 8.99	0.85 : 8.99
Change from Baseline						
n	6	14	20	12	28	40
Mean (SD)	-4.565 (3.0696)	-3.850 (3.5344)	-4.065 (3.3376)	-2.747 (2.3663)	-3.053 (3.2148)	-2.961 (2.9588)
Median	-4.705	-2.385	-3.315	-2.215	-2.185	-2.185
Q1 : Q3	-5.67 : -1.89	-6.19 : -1.50	-5.93 : -1.62	-4.04 : -1.14	-4.06 : -1.12	-4.04 : -1.12
Min : Max	-9.51 : -0.91	-12.62 : 0.88	-12.62 : 0.88	-8.81 : -0.16	-14.50 : 1.61	-14.50 : 1.61
Percent Change from Baseline						
n	6	14	20	12	28	40
Mean (SD)	-55.23 (20.739)	-40.04 (24.394)	-44.60 (23.903)	-45.62 (19.390)	-41.40 (44.712)	-42.67 (38.651)
Median	-54.42	-41.65	-44.52	-47.63	-48.07	-47.67
Q1 : Q3	-68.6 : -44.3	-58.7 : -30.8	-60.1 : -32.0	-62.4 : -33.4	-65.6 : -40.9	-64.4 : -38.3
Min : Max	-84.6 : -25.1	-73.6 : 17.3	-84.6 : 17.3	-69.9 : -10.2	-85.4 : 135.3	-85.4 : 135.3

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8000_ldlsi_sum_nul.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.43 Calculated LDL-C Over Time (On-treatment estimand) in SI Units - Raw Data Description: Subgroup Analysis According to Null/Null Mutation in Both LDLR or LDLRAP1 Alleles
Open-label Safety Analysis Set - OLTP

	Null/Null			Not Null/Null		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mmol/L)	DB Placebo IV Q4W (N=6)	Q4W (N=15)	Total (N=21)	DB Placebo IV Q4W (N=14)	Q4W (N=29)	Total (N=43)
Week 40						
Value						
n	6	15	21	13	26	39
Mean (SD)	3.677 (2.4610)	4.441 (2.4632)	4.222 (2.4262)	2.392 (1.2686)	2.760 (1.8617)	2.637 (1.6791)
Median	2.755	3.240	3.030	2.200	2.525	2.410
Q1 : Q3	2.38 : 6.01	2.64 : 6.50	2.64 : 6.01	1.55 : 2.75	1.42 : 3.08	1.42 : 3.08
Min : Max	0.83 : 7.33	1.86 : 10.57	0.83 : 10.57	0.54 : 4.56	0.83 : 8.88	0.54 : 8.88
Change from Baseline						
n	6	15	21	13	26	39
Mean (SD)	-4.085 (2.8573)	-3.751 (3.8920)	-3.846 (3.5593)	-3.016 (2.6709)	-3.211 (3.3074)	-3.146 (3.0754)
Median	-3.950	-2.900	-2.900	-2.850	-2.350	-2.660
Q1 : Q3	-5.57 : -1.89	-6.58 : -1.04	-5.57 : -1.89	-4.38 : -0.75	-4.77 : -1.66	-4.45 : -1.27
Min : Max	-8.34 : -0.81	-13.08 : 3.68	-13.08 : 3.68	-9.17 : -0.10	-14.61 : 1.79	-14.61 : 1.79
Percent Change from Baseline						
n	6	15	21	13	26	39
Mean (SD)	-50.42 (24.267)	-40.47 (31.752)	-43.31 (29.567)	-48.97 (23.659)	-40.91 (49.564)	-43.60 (42.518)
Median	-48.74	-48.24	-48.24	-56.44	-56.79	-56.44
Q1 : Q3	-67.4 : -28.4	-61.3 : -22.2	-61.3 : -28.4	-66.6 : -36.8	-68.3 : -37.4	-67.7 : -36.8
Min : Max	-86.9 : -22.3	-76.3 : 53.4	-86.9 : 53.4	-83.7 : -3.5	-83.0 : 150.4	-83.7 : 150.4

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8000_ldlsi_sum_nul.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.43 Calculated LDL-C Over Time (On-treatment estimand) in SI Units - Raw Data Description: Subgroup Analysis According to Null/Null Mutation in Both LDLR or LDLRAP1 Alleles

Open-label Safety Analysis Set - OLTP

	Null/Null			Not Null/Null		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mmol/L)	DB Placebo IV Q4W (N=6)	Q4W (N=15)	Total (N=21)	DB Placebo IV Q4W (N=14)	Q4W (N=29)	Total (N=43)
Week 44						
Value						
n	6	14	20	13	25	38
Mean (SD)	3.020 (1.5790)	5.073 (3.5445)	4.457 (3.1912)	2.138 (1.2835)	2.836 (1.8916)	2.597 (1.7227)
Median	2.680	4.650	4.260	1.760	2.310	2.020
Q1 : Q3	1.50 : 4.69	2.77 : 5.41	2.58 : 5.14	1.35 : 2.56	1.66 : 3.24	1.48 : 3.24
Min : Max	1.42 : 5.15	1.71 : 16.11	1.42 : 16.11	0.62 : 4.45	0.21 : 7.98	0.21 : 7.98
Change from Baseline						
n	6	14	20	13	25	38
Mean (SD)	-4.742 (3.4327)	-3.145 (4.5690)	-3.624 (4.2365)	-3.270 (2.4937)	-3.003 (3.6612)	-3.094 (3.2754)
Median	-4.085	-2.150	-2.805	-2.950	-2.040	-2.560
Q1 : Q3	-5.44 : -2.77	-6.97 : -1.19	-6.21 : -1.30	-4.43 : -1.74	-4.53 : -1.60	-4.53 : -1.60
Min : Max	-10.98 : -1.09	-12.59 : 6.71	-12.59 : 6.71	-9.22 : -0.28	-15.51 : 4.58	-15.51 : 4.58
Percent Change from Baseline						
n	6	14	20	13	25	38
Mean (SD)	-57.85 (18.965)	-33.19 (37.768)	-40.59 (34.713)	-56.06 (19.103)	-33.15 (76.331)	-40.99 (63.395)
Median	-65.37	-45.97	-51.51	-58.42	-51.95	-58.16
Q1 : Q3	-70.1 : -38.6	-54.0 : -19.2	-65.4 : -30.6	-69.8 : -51.4	-65.8 : -38.6	-66.3 : -38.8
Min : Max	-77.6 : -30.0	-73.4 : 71.4	-77.6 : 71.4	-79.5 : -10.2	-90.4 : 248.9	-90.4 : 248.9

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8000_ldlsi_sum_nul.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.43 Calculated LDL-C Over Time (On-treatment estimand) in SI Units - Raw Data Description: Subgroup Analysis According to Null/Null Mutation in Both LDLR or LDLRAP1 Alleles
Open-label Safety Analysis Set - OLTP

	Null/Null			Not Null/Null		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mmol/L)	DB Placebo IV Q4W (N=6)	Q4W (N=15)	Total (N=21)	DB Placebo IV Q4W (N=14)	Q4W (N=29)	Total (N=43)
Week 48						
Value						
n	5	14	19	11	28	39
Mean (SD)	3.688 (2.8850)	4.069 (1.8756)	3.968 (2.1023)	2.372 (1.5924)	2.777 (2.0434)	2.663 (1.9152)
Median	2.330	3.460	3.240	2.020	2.435	2.310
Q1 : Q3	1.58 : 6.68	2.80 : 4.97	2.33 : 6.22	1.32 : 4.48	1.28 : 3.15	1.32 : 3.19
Min : Max	0.93 : 6.92	1.42 : 7.98	0.93 : 7.98	0.36 : 4.82	0.65 : 10.13	0.36 : 10.13
Change from Baseline						
n	5	14	19	11	28	39
Mean (SD)	-3.974 (3.1155)	-4.149 (3.5922)	-4.103 (3.3887)	-3.656 (2.4702)	-2.987 (3.0063)	-3.176 (2.8497)
Median	-2.690	-2.655	-2.690	-3.060	-2.215	-2.360
Q1 : Q3	-5.42 : -1.71	-6.86 : -1.42	-6.86 : -1.42	-5.62 : -1.48	-4.45 : -1.33	-4.79 : -1.48
Min : Max	-8.75 : -1.30	-12.80 : -0.73	-12.80 : -0.73	-8.45 : -0.54	-13.36 : 1.99	-13.36 : 1.99
Percent Change from Baseline						
n	5	14	19	11	28	39
Mean (SD)	-52.08 (25.050)	-45.45 (21.813)	-47.19 (22.183)	-57.49 (22.275)	-41.34 (46.847)	-45.89 (41.763)
Median	-55.84	-52.51	-52.56	-54.26	-52.01	-54.26
Q1 : Q3	-63.0 : -35.8	-63.2 : -26.9	-63.2 : -26.9	-65.9 : -46.5	-66.9 : -37.8	-65.9 : -38.5
Min : Max	-85.4 : -20.4	-74.6 : -13.5	-85.4 : -13.5	-93.5 : -18.9	-83.3 : 117.6	-93.5 : 117.6

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8000_ldlsi_sum_nul.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.43 Calculated LDL-C Over Time (On-treatment estimand) in SI Units - Raw Data Description: Subgroup Analysis According to Null/Null Mutation in Both LDLR or LDLRAP1 Alleles
Open-label Safety Analysis Set - OLTP

	Null/Null			Not Null/Null		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mmol/L)	DB Placebo IV Q4W (N=6)	Q4W (N=15)	Total (N=21)	DB Placebo IV Q4W (N=14)	Q4W (N=29)	Total (N=43)
FU - W4						
Value						
n	0	2	2	0	2	2
Mean (SD)		3.185 (1.7607)	3.185 (1.7607)		3.925 (2.2132)	3.925 (2.2132)
Median		3.185	3.185		3.925	3.925
Q1 : Q3		1.94 : 4.43	1.94 : 4.43		2.36 : 5.49	2.36 : 5.49
Min : Max		1.94 : 4.43	1.94 : 4.43		2.36 : 5.49	2.36 : 5.49
Change from Baseline						
n	0	2	2	0	2	2
Mean (SD)		-1.890 (2.3052)	-1.890 (2.3052)		-3.210 (0.1131)	-3.210 (0.1131)
Median		-1.890	-1.890		-3.210	-3.210
Q1 : Q3		-3.52 : -0.26	-3.52 : -0.26		-3.29 : -3.13	-3.29 : -3.13
Min : Max		-3.52 : -0.26	-3.52 : -0.26		-3.29 : -3.13	-3.29 : -3.13
Percent Change from Baseline						
n	0	2	2	0	2	2
Mean (SD)		-35.01 (41.666)	-35.01 (41.666)		-47.24 (13.818)	-47.24 (13.818)
Median		-35.01	-35.01		-47.24	-47.24
Q1 : Q3		-64.5 : -5.5	-64.5 : -5.5		-57.0 : -37.5	-57.0 : -37.5
Min : Max		-64.5 : -5.5	-64.5 : -5.5		-57.0 : -37.5	-57.0 : -37.5

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8000_ldlsi_sum_nul.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.50 Calculated LDL-C Over Time (On-treatment estimand) in Conventional Units - Raw Data Description: Subgroup Analysis According to Receptor-negative Mutation in Both LDLR or LDLRAP1 Alleles
Open-label Safety Analysis Set - OLTP

	Negative/Negative			Not Negative/Negative		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mg/dL)	DB Placebo IV Q4W (N=7)	Q4W (N=5)	Total (N=12)	DB Placebo IV Q4W (N=13)	Q4W (N=39)	Total (N=52)
Baseline						
Value						
n	7	5	12	13	39	52
Mean (SD)	261.6 (131.09)	328.4 (81.24)	289.4 (113.83)	222.3 (154.20)	248.0 (177.98)	241.6 (171.24)
Median	319.0	332.0	321.5	179.0	181.0	180.5
Q1 : Q3	140 : 348	302 : 363	229 : 356	117 : 209	148 : 333	137 : 296
Min : Max	39 : 416	212 : 433	39 : 433	108 : 605	46 : 907	46 : 907
Week 28						
Value						
n	7	4	11	12	37	49
Mean (SD)	132.4 (73.20)	196.8 (51.69)	155.8 (71.20)	116.6 (79.16)	117.4 (80.69)	117.2 (79.49)
Median	124.0	187.0	162.0	86.0	103.0	96.0
Q1 : Q3	54 : 202	156 : 238	107 : 212	68 : 150	63 : 140	63 : 145
Min : Max	36 : 229	150 : 263	36 : 263	34 : 313	28 : 325	28 : 325
Change from Baseline						
n	7	4	11	12	37	49
Mean (SD)	-129.1 (87.55)	-160.8 (18.82)	-140.6 (70.42)	-111.8 (100.58)	-130.0 (134.60)	-125.5 (126.37)
Median	-122.0	-160.5	-151.0	-76.5	-81.0	-81.0
Q1 : Q3	-195 : -33	-176 : -146	-191 : -119	-159 : -55	-183 : -55	-180 : -55
Min : Max	-241 : -3	-182 : -140	-241 : -3	-293 : 45	-594 : 39	-594 : 45

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8100_ldlcv_sum_neg.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.50 Calculated LDL-C Over Time (On-treatment estimand) in Conventional Units - Raw Data Description: Subgroup Analysis According to Receptor-negative Mutation
in Both LDLR or LDLRAP1 Alleles
Open-label Safety Analysis Set - OLTP

	Negative/Negative			Not Negative/Negative		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mg/dL)	DB Placebo IV Q4W (N=7)	Q4W (N=5)	Total (N=12)	DB Placebo IV Q4W (N=13)	Q4W (N=39)	Total (N=52)
Week 28						
Percent Change from Baseline						
n	7	4	11	12	37	49
Mean (SD)	-42.88 (24.166)	-45.51 (6.874)	-43.83 (19.140)	-43.76 (30.272)	-44.80 (32.787)	-44.54 (31.882)
Median	-37.65	-43.98	-41.60	-48.99	-52.94	-49.72
Q1 : Q3	-61.1 : -23.6	-50.6 : -40.4	-57.9 : -34.2	-58.9 : -36.3	-67.3 : -38.4	-65.5 : -37.6
Min : Max	-78.0 : -7.7	-54.8 : -39.3	-78.0 : -7.7	-83.2 : 40.9	-92.4 : 56.5	-92.4 : 56.5
Week 32						
Value						
n	7	5	12	12	37	49
Mean (SD)	120.6 (70.26)	183.4 (93.63)	146.8 (83.23)	99.9 (45.22)	116.7 (74.56)	112.6 (68.50)
Median	117.0	135.0	126.5	83.5	102.0	99.0
Q1 : Q3	39 : 198	118 : 250	101 : 205	66 : 131	60 : 152	61 : 152
Min : Max	33 : 212	100 : 314	33 : 314	51 : 180	18 : 319	18 : 319

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8100_ldlcv_sum_neg.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.50 Calculated LDL-C Over Time (On-treatment estimand) in Conventional Units - Raw Data Description: Subgroup Analysis According to Receptor-negative Mutation
in Both LDLR or LDLRAP1 Alleles
Open-label Safety Analysis Set - OLTP

| | Negative/Negative | | | Not Negative/Negative | | |
| | | DB Evinacumab 15 mg/kg IV | | | DB Evinacumab 15 mg/kg IV | |
Calculated LDL-C (mg/dL)	DB Placebo IV Q4W (N=7)	Q4W (N=5)	Total (N=12)	DB Placebo IV Q4W (N=13)	Q4W (N=39)	Total (N=52)
Week 32						
Change from Baseline						
n	7	5	12	12	37	49
Mean (SD)	-141.0 (95.44)	-145.0 (65.18)	-142.7 (80.73)	-123.5 (137.89)	-133.3 (138.71)	-130.9 (137.14)
Median	-150.0	-167.0	-158.5	-82.5	-92.0	-92.0
Q1 : Q3	-206 : -39	-183 : -112	-204 : -81	-141 : -54	-190 : -48	-175 : -52
Min : Max	-272 : -6	-214 : -49	-272 : -6	-453 : 65	-588 : 65	-588 : 65
Percent Change from Baseline						
n	7	5	12	12	37	49
Mean (SD)	-47.67 (24.194)	-45.67 (19.644)	-46.84 (21.463)	-45.02 (35.009)	-42.46 (44.281)	-43.09 (41.865)
Median	-43.10	-52.83	-47.97	-52.83	-54.76	-54.76
Q1 : Q3	-65.4 : -27.9	-55.3 : -42.3	-63.9 : -31.2	-62.0 : -42.9	-69.0 : -28.7	-68.2 : -33.9
Min : Max	-84.1 : -15.4	-64.5 : -13.5	-84.1 : -13.5	-74.9 : 59.1	-91.7 : 141.3	-91.7 : 141.3

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8100_ldlcv_sum_neg.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.50 Calculated LDL-C Over Time (On-treatment estimand) in Conventional Units - Raw Data Description: Subgroup Analysis According to Receptor-negative Mutation
in Both LDLR or LDLRAP1 Alleles
Open-label Safety Analysis Set - OLTP

	Negative/Negative			Not Negative/Negative		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mg/dL)	DB Placebo IV Q4W (N=7)	Q4W (N=5)	Total (N=12)	DB Placebo IV Q4W (N=13)	Q4W (N=39)	Total (N=52)
Week 36						
Value						
n	7	5	12	11	37	48
Mean (SD)	128.0 (84.11)	205.4 (84.50)	160.3 (89.69)	99.3 (55.96)	117.7 (74.25)	113.5 (70.36)
Median	105.0	202.0	152.5	81.0	100.0	96.5
Q1 : Q3	38 : 186	137 : 284	103 : 234	70 : 107	65 : 136	68 : 131
Min : Max	33 : 266	108 : 296	33 : 296	41 : 238	38 : 347	38 : 347
Change from Baseline						
n	7	5	12	11	37	48
Mean (SD)	-133.6 (81.92)	-123.0 (49.71)	-129.2 (67.74)	-126.7 (118.86)	-128.8 (135.08)	-128.3 (130.32)
Median	-156.0	-104.0	-149.5	-76.0	-83.0	-82.5
Q1 : Q3	-207 : -35	-149 : -100	-179 : -84	-162 : -52	-187 : -43	-182 : -44
Min : Max	-219 : -6	-195 : -67	-219 : -6	-367 : -11	-560 : 62	-560 : 62
Percent Change from Baseline						
n	7	5	12	11	37	48
Mean (SD)	-46.33 (24.069)	-38.75 (15.557)	-43.17 (20.474)	-50.33 (17.730)	-41.23 (41.032)	-43.31 (37.033)
Median	-46.55	-34.41	-41.30	-50.67	-46.37	-47.62
Q1 : Q3	-68.7 : -25.0	-49.1 : -33.1	-53.9 : -29.1	-64.3 : -44.2	-64.3 : -39.2	-64.3 : -40.0
Min : Max	-84.5 : -15.4	-58.7 : -18.5	-84.5 : -15.4	-69.8 : -10.0	-85.4 : 134.8	-85.4 : 134.8

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8100_ldlcv_sum_neg.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.50 Calculated LDL-C Over Time (On-treatment estimand) in Conventional Units - Raw Data Description: Subgroup Analysis According to Receptor-negative Mutation
in Both LDLR or LDLRAP1 Alleles
Open-label Safety Analysis Set - OLTP

	Negative/Negative			Not Negative/Negative		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mg/dL)	DB Placebo IV Q4W (N=7)	Q4W (N=5)	Total (N=12)	DB Placebo IV Q4W (N=13)	Q4W (N=39)	Total (N=52)
Week 40						
Value						
n	7	5	12	12	36	48
Mean (SD)	120.6 (77.57)	168.0 (85.53)	140.3 (80.86)	100.8 (64.74)	125.1 (85.94)	119.0 (81.20)
Median	109.0	125.0	121.0	88.5	106.0	102.0
Q1 : Q3	32 : 176	117 : 251	92 : 204	68 : 105	71 : 128	71 : 123
Min : Max	21 : 232	79 : 268	21 : 268	33 : 283	32 : 408	32 : 408
Change from Baseline						
n	7	5	12	12	36	48
Mean (SD)	-141.0 (93.34)	-160.4 (38.38)	-149.1 (73.40)	-122.7 (113.53)	-127.6 (143.15)	-126.4 (135.21)
Median	-172.0	-165.0	-168.5	-91.5	-82.5	-82.5
Q1 : Q3	-215 : -31	-185 : -133	-210 : -102	-163 : -42	-200 : -45	-190 : -45
Min : Max	-246 : -18	-207 : -112	-246 : -18	-354 : -4	-564 : 142	-564 : 142
Percent Change from Baseline						
n	7	5	12	12	36	48
Mean (SD)	-51.37 (22.343)	-51.06 (15.361)	-51.24 (18.925)	-48.22 (24.537)	-39.31 (45.939)	-41.54 (41.565)
Median	-49.43	-61.26	-54.28	-54.82	-49.26	-50.99
Q1 : Q3	-67.4 : -28.4	-62.3 : -38.1	-62.5 : -34.5	-67.1 : -31.8	-66.2 : -35.6	-67.1 : -35.6
Min : Max	-86.9 : -22.1	-62.7 : -30.9	-86.9 : -22.1	-83.7 : -3.6	-82.9 : 150.0	-83.7 : 150.0

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8100_ldlcv_sum_neg.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.50 Calculated LDL-C Over Time (On-treatment estimand) in Conventional Units - Raw Data Description: Subgroup Analysis According to Receptor-negative Mutation
in Both LDLR or LDLRAP1 Alleles
Open-label Safety Analysis Set - OLTP

	Negative/Negative			Not Negative/Negative		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mg/dL)	DB Placebo IV Q4W (N=7)	Q4W (N=5)	Total (N=12)	DB Placebo IV Q4W (N=13)	Q4W (N=39)	Total (N=52)
Week 44						
Value						
n	7	4	11	12	35	47
Mean (SD)	118.1 (63.68)	276.0 (238.82)	175.5 (160.89)	78.8 (44.41)	125.0 (73.88)	113.2 (70.14)
Median	109.0	196.5	153.0	64.5	107.0	96.0
Q1 : Q3	55 : 172	121 : 431	89 : 199	53 : 90	66 : 183	61 : 147
Min : Max	28 : 199	89 : 622	28 : 622	24 : 181	8 : 308	8 : 308
Change from Baseline						
n	7	4	11	12	35	47
Mean (SD)	-143.4 (88.68)	-59.0 (214.15)	-112.7 (142.44)	-144.6 (122.57)	-124.7 (146.67)	-129.8 (139.89)
Median	-176.0	-151.0	-176.0	-110.5	-79.0	-83.0
Q1 : Q3	-210 : -42	-186 : 68	-193 : -42	-153 : -72	-188 : -49	-175 : -56
Min : Max	-250 : -11	-193 : 259	-250 : 259	-424 : -11	-599 : 177	-599 : 177
Percent Change from Baseline						
n	7	4	11	12	35	47
Mean (SD)	-50.12 (18.785)	-21.29 (62.015)	-39.64 (39.712)	-60.41 (18.067)	-34.55 (65.586)	-41.15 (58.201)
Median	-50.57	-49.24	-50.57	-65.59	-51.03	-53.27
Q1 : Q3	-65.8 : -30.0	-56.0 : 13.4	-60.1 : -30.0	-70.4 : -55.1	-65.9 : -35.1	-69.7 : -36.5
Min : Max	-77.6 : -28.2	-58.0 : 71.3	-77.6 : 71.3	-79.5 : -10.0	-90.5 : 249.3	-90.5 : 249.3

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8100_ldlcv_sum_neg.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.50 Calculated LDL-C Over Time (On-treatment estimand) in Conventional Units - Raw Data Description: Subgroup Analysis According to Receptor-negative Mutation
in Both LDLR or LDLRAP1 Alleles
Open-label Safety Analysis Set - OLTP

	Negative/Negative			Not Negative/Negative		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mg/dL)	DB Placebo IV Q4W (N=7)	Q4W (N=5)	Total (N=12)	DB Placebo IV Q4W (N=13)	Q4W (N=39)	Total (N=52)
Week 48						
Value						
n	5	4	9	11	38	49
Mean (SD)	148.6 (86.71)	198.8 (104.01)	170.9 (92.28)	88.7 (73.41)	115.9 (73.88)	109.8 (73.91)
Median	173.0	195.5	173.0	74.0	109.5	92.0
Q1 : Q3	90 : 186	111 : 287	96 : 258	51 : 89	63 : 136	61 : 127
Min : Max	36 : 258	96 : 308	36 : 308	14 : 267	25 : 391	14 : 391
Change from Baseline						
n	5	4	9	11	38	49
Mean (SD)	-146.0 (85.51)	-136.3 (65.73)	-141.7 (72.82)	-144.5 (109.59)	-129.7 (129.42)	-133.0 (124.31)
Median	-162.0	-141.5	-162.0	-106.0	-85.5	-91.0
Q1 : Q3	-209 : -66	-187 : -86	-207 : -66	-217 : -57	-185 : -47	-188 : -55
Min : Max	-243 : -50	-207 : -55	-243 : -50	-338 : -21	-516 : 77	-516 : 77
Percent Change from Baseline						
n	5	4	9	11	38	49
Mean (SD)	-49.27 (24.538)	-42.70 (20.869)	-46.35 (21.826)	-58.77 (22.004)	-42.70 (41.686)	-46.31 (38.552)
Median	-46.55	-46.64	-46.55	-55.87	-52.54	-54.36
Q1 : Q3	-58.4 : -35.7	-58.5 : -26.9	-58.4 : -35.7	-65.9 : -50.7	-66.5 : -33.5	-65.9 : -34.3
Min : Max	-85.3 : -20.4	-62.3 : -15.2	-85.3 : -15.2	-93.5 : -19.1	-83.3 : 117.4	-93.5 : 117.4

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8100_ldlcv_sum_neg.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.50 Calculated LDL-C Over Time (On-treatment estimand) in Conventional Units - Raw Data Description: Subgroup Analysis According to Receptor-negative Mutation
in Both LDLR or LDLRAP1 Alleles
Open-label Safety Analysis Set - OLTP

	Negative/Negative			Not Negative/Negative		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mg/dL)	DB Placebo IV Q4W (N=7)	Q4W (N=5)	Total (N=12)	DB Placebo IV Q4W (N=13)	Q4W (N=39)	Total (N=52)
FU - W4						
Value						
n	0	1	1	0	3	3
Mean (SD)		91.0 (.)	91.0 (.)		152.7 (70.32)	152.7 (70.32)
Median		91.0	91.0		171.0	171.0
Q1 : Q3		91 : 91	91 : 91		75 : 212	75 : 212
Min : Max		91 : 91	91 : 91		75 : 212	75 : 212
Change from Baseline						
n	0	1	1	0	3	3
Mean (SD)		-121.0 (.)	-121.0 (.)		-91.0 (70.29)	-91.0 (70.29)
Median		-121.0	-121.0		-127.0	-127.0
Q1 : Q3		-121 : -121	-121 : -121		-136 : -10	-136 : -10
Min : Max		-121 : -121	-121 : -121		-136 : -10	-136 : -10
Percent Change from Baseline						
n	0	1	1	0	3	3
Mean (SD)		-57.08 (.)	-57.08 (.)		-35.81 (29.500)	-35.81 (29.500)
Median		-57.08	-57.08		-37.46	-37.46
Q1 : Q3		-57.1 : -57.1	-57.1 : -57.1		-64.5 : -5.5	-64.5 : -5.5
Min : Max		-57.1 : -57.1	-57.1 : -57.1		-64.5 : -5.5	-64.5 : -5.5

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8100_ldlcv_sum_neg.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.51 Calculated LDL-C Over Time (On-treatment estimand) in SI Units - Raw Data Description: Subgroup Analysis According to Receptor-negative Mutation in Both LDLR or LDLRAP1 Alleles
Open-label Safety Analysis Set - OLTP

	Negative/Negative			Not Negative/Negative		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mmol/L)	DB Placebo IV Q4W (N=7)	Q4W (N=5)	Total (N=12)	DB Placebo IV Q4W (N=13)	Q4W (N=39)	Total (N=52)
Baseline						
Value						
n	7	5	12	13	39	52
Mean (SD)	6.774 (3.3930)	8.504 (2.1028)	7.495 (2.9463)	5.758 (3.9939)	6.423 (4.6098)	6.257 (4.4352)
Median	8.260	8.600	8.325	4.640	4.690	4.675
Q1 : Q3	3.63 : 9.01	7.82 : 9.40	5.92 : 9.21	3.03 : 5.41	3.83 : 8.62	3.55 : 7.66
Min : Max	1.01 : 10.77	5.49 : 11.21	1.01 : 11.21	2.80 : 15.67	1.19 : 23.49	1.19 : 23.49
Week 28						
Value						
n	7	4	11	12	37	49
Mean (SD)	3.429 (1.8954)	5.098 (1.3354)	4.035 (1.8438)	3.020 (2.0510)	3.040 (2.0902)	3.035 (2.0593)
Median	3.210	4.845	4.200	2.225	2.670	2.490
Q1 : Q3	1.40 : 5.23	4.05 : 6.15	2.77 : 5.49	1.76 : 3.89	1.63 : 3.63	1.63 : 3.76
Min : Max	0.93 : 5.93	3.89 : 6.81	0.93 : 6.81	0.88 : 8.11	0.73 : 8.42	0.73 : 8.42
Change from Baseline						
n	7	4	11	12	37	49
Mean (SD)	-3.346 (2.2658)	-4.160 (0.4879)	-3.642 (1.8223)	-2.894 (2.6044)	-3.366 (3.4860)	-3.251 (3.2727)
Median	-3.160	-4.155	-3.910	-1.980	-2.090	-2.090
Q1 : Q3	-5.05 : -0.86	-4.56 : -3.77	-4.95 : -3.08	-4.12 : -1.43	-4.74 : -1.43	-4.66 : -1.43
Min : Max	-6.24 : -0.08	-4.71 : -3.62	-6.24 : -0.08	-7.59 : 1.16	-15.38 : 1.01	-15.38 : 1.16

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8100_ldlsi_sum_neg.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.51 Calculated LDL-C Over Time (On-treatment estimand) in SI Units - Raw Data Description: Subgroup Analysis According to Receptor-negative Mutation in Both LDLR or LDLRAP1 Alleles
Open-label Safety Analysis Set - OLTP

	Negative/Negative			Not Negative/Negative		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mmol/L)	DB Placebo IV Q4W (N=7)	Q4W (N=5)	Total (N=12)	DB Placebo IV Q4W (N=13)	Q4W (N=39)	Total (N=52)
Week 28						
Percent Change from Baseline						
n	7	4	11	12	37	49
Mean (SD)	-42.93 (24.095)	-45.48 (6.851)	-43.85 (19.081)	-43.76 (30.228)	-44.80 (32.767)	-44.55 (31.857)
Median	-37.66	-43.94	-41.60	-49.01	-52.92	-49.78
Q1 : Q3	-61.1 : -23.7	-50.5 : -40.4	-57.9 : -34.2	-58.8 : -36.2	-67.4 : -38.3	-65.5 : -37.5
Min : Max	-78.0 : -7.9	-54.8 : -39.3	-78.0 : -7.9	-83.2 : 40.7	-92.4 : 56.3	-92.4 : 56.3
Week 32						
Value						
n	7	5	12	12	37	49
Mean (SD)	3.123 (1.8208)	4.752 (2.4239)	3.802 (2.1561)	2.588 (1.1713)	3.023 (1.9315)	2.916 (1.7743)
Median	3.030	3.500	3.280	2.165	2.640	2.560
Q1 : Q3	1.01 : 5.13	3.06 : 6.48	2.61 : 5.31	1.71 : 3.38	1.55 : 3.94	1.58 : 3.94
Min : Max	0.85 : 5.49	2.59 : 8.13	0.85 : 8.13	1.32 : 4.66	0.47 : 8.26	0.47 : 8.26

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8100_ldlsi_sum_neg.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.51 Calculated LDL-C Over Time (On-treatment estimand) in SI Units - Raw Data Description: Subgroup Analysis According to Receptor-negative Mutation in Both
LDLR or LDLRAP1 Alleles
Open-label Safety Analysis Set - OLTP

	Negative/Negative			Not Negative/Negative		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mmol/L)	DB Placebo IV Q4W (N=7)	Q4W (N=5)	Total (N=12)	DB Placebo IV Q4W (N=13)	Q4W (N=39)	Total (N=52)
Week 32						
Change from Baseline						
n	7	5	12	12	37	49
Mean (SD)	-3.651 (2.4701)	-3.752 (1.6854)	-3.693 (2.0890)	-3.200 (3.5701)	-3.454 (3.5932)	-3.391 (3.5519)
Median	-3.880	-4.320	-4.100	-2.135	-2.380	-2.380
Q1 : Q3	-5.34 : -1.01	-4.73 : -2.90	-5.29 : -2.09	-3.64 : -1.40	-4.92 : -1.24	-4.53 : -1.35
Min : Max	-7.04 : -0.16	-5.54 : -1.27	-7.04 : -0.16	-11.73 : 1.68	-15.23 : 1.68	-15.23 : 1.68
Percent Change from Baseline						
n	7	5	12	12	37	49
Mean (SD)	-47.72 (24.099)	-45.64 (19.625)	-46.86 (21.401)	-45.06 (34.966)	-42.47 (44.263)	-43.10 (41.843)
Median	-43.06	-52.82	-47.94	-52.80	-54.73	-54.73
Q1 : Q3	-65.4 : -27.8	-55.2 : -42.2	-63.9 : -31.2	-62.1 : -43.0	-69.3 : -28.9	-68.3 : -34.0
Min : Max	-84.1 : -15.8	-64.4 : -13.5	-84.1 : -13.5	-74.9 : 58.9	-91.7 : 141.2	-91.7 : 141.2

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8100_ldlsi_sum_neg.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.51 Calculated LDL-C Over Time (On-treatment estimand) in SI Units - Raw Data Description: Subgroup Analysis According to Receptor-negative Mutation in Both LDLR or LDLRAP1 Alleles

Open-label Safety Analysis Set - OLTP

	Negative/Negative			Not Negative/Negative		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mmol/L)	DB Placebo IV Q4W (N=7)	Q4W (N=5)	Total (N=12)	DB Placebo IV Q4W (N=13)	Q4W (N=39)	Total (N=52)
Week 36						
Value						
n	7	5	12	11	37	48
Mean (SD)	3.314 (2.1804)	5.322 (2.1895)	4.151 (2.3249)	2.570 (1.4483)	3.048 (1.9233)	2.939 (1.8223)
Median	2.720	5.230	3.950	2.100	2.590	2.500
Q1 : Q3	0.98 : 4.82	3.55 : 7.36	2.66 : 6.06	1.81 : 2.77	1.68 : 3.52	1.75 : 3.38
Min : Max	0.85 : 6.89	2.80 : 7.67	0.85 : 7.67	1.06 : 6.16	0.98 : 8.99	0.98 : 8.99
Change from Baseline						
n	7	5	12	11	37	48
Mean (SD)	-3.460 (2.1202)	-3.182 (1.2881)	-3.344 (1.7538)	-3.285 (3.0794)	-3.337 (3.4985)	-3.325 (3.3754)
Median	-4.040	-2.690	-3.865	-1.970	-2.150	-2.140
Q1 : Q3	-5.37 : -0.91	-3.85 : -2.59	-4.62 : -2.16	-4.20 : -1.35	-4.84 : -1.12	-4.70 : -1.15
Min : Max	-5.67 : -0.16	-5.05 : -1.73	-5.67 : -0.16	-9.51 : -0.29	-14.50 : 1.61	-14.50 : 1.61
Percent Change from Baseline						
n	7	5	12	11	37	48
Mean (SD)	-46.40 (23.983)	-38.72 (15.564)	-43.20 (20.432)	-50.36 (17.714)	-41.25 (41.074)	-43.34 (37.067)
Median	-46.50	-34.34	-41.26	-50.64	-46.34	-47.67
Q1 : Q3	-68.6 : -25.1	-49.0 : -33.1	-53.9 : -29.1	-64.4 : -44.3	-64.3 : -39.2	-64.4 : -39.9
Min : Max	-84.6 : -15.8	-58.7 : -18.4	-84.6 : -15.8	-69.9 : -10.2	-85.4 : 135.3	-85.4 : 135.3

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8100_ldlsi_sum_neg.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.51 Calculated LDL-C Over Time (On-treatment estimand) in SI Units - Raw Data Description: Subgroup Analysis According to Receptor-negative Mutation in Both LDLR or LDLRAP1 Alleles
Open-label Safety Analysis Set - OLTP

	Negative/Negative			Not Negative/Negative		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mmol/L)	DB Placebo IV Q4W (N=7)	Q4W (N=5)	Total (N=12)	DB Placebo IV Q4W (N=13)	Q4W (N=39)	Total (N=52)
Week 40						
Value						
n	7	5	12	12	36	48
Mean (SD)	3.121 (2.0100)	4.352 (2.2133)	3.634 (2.0944)	2.608 (1.6780)	3.239 (2.2260)	3.081 (2.1036)
Median	2.820	3.240	3.135	2.290	2.745	2.640
Q1 : Q3	0.83 : 4.56	3.03 : 6.50	2.37 : 5.29	1.75 : 2.72	1.83 : 3.32	1.83 : 3.17
Min : Max	0.54 : 6.01	2.05 : 6.94	0.54 : 6.94	0.85 : 7.33	0.83 : 10.57	0.83 : 10.57
Change from Baseline						
n	7	5	12	12	36	48
Mean (SD)	-3.653 (2.4157)	-4.152 (0.9943)	-3.861 (1.8996)	-3.179 (2.9405)	-3.305 (3.7079)	-3.274 (3.5021)
Median	-4.450	-4.270	-4.360	-2.370	-2.135	-2.135
Q1 : Q3	-5.57 : -0.81	-4.79 : -3.44	-5.44 : -2.64	-4.23 : -1.09	-5.18 : -1.16	-4.92 : -1.16
Min : Max	-6.37 : -0.47	-5.36 : -2.90	-6.37 : -0.47	-9.17 : -0.10	-14.61 : 3.68	-14.61 : 3.68
Percent Change from Baseline						
n	7	5	12	12	36	48
Mean (SD)	-51.44 (22.299)	-51.04 (15.346)	-51.27 (18.892)	-48.25 (24.571)	-39.32 (45.977)	-41.55 (41.603)
Median	-49.39	-61.25	-54.27	-54.83	-49.27	-51.06
Q1 : Q3	-67.4 : -28.4	-62.3 : -38.1	-62.5 : -34.5	-67.2 : -31.8	-66.3 : -35.7	-67.2 : -35.7
Min : Max	-86.9 : -22.3	-62.7 : -30.9	-86.9 : -22.3	-83.7 : -3.5	-83.0 : 150.4	-83.7 : 150.4

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8100_ldlsi_sum_neg.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.51 Calculated LDL-C Over Time (On-treatment estimand) in SI Units - Raw Data Description: Subgroup Analysis According to Receptor-negative Mutation in Both LDLR or LDLRAP1 Alleles
Open-label Safety Analysis Set - OLTP

	Negative/Negative			Not Negative/Negative		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mmol/L)	DB Placebo IV Q4W (N=7)	Q4W (N=5)	Total (N=12)	DB Placebo IV Q4W (N=13)	Q4W (N=39)	Total (N=52)
Week 44						
Value						
n	7	4	11	12	35	47
Mean (SD)	3.059 (1.6474)	7.150 (6.1846)	4.546 (4.1670)	2.042 (1.1511)	3.237 (1.9129)	2.932 (1.8164)
Median	2.820	5.090	3.960	1.670	2.770	2.490
Q1 : Q3	1.42 : 4.45	3.14 : 11.17	2.31 : 5.15	1.38 : 2.33	1.71 : 4.74	1.58 : 3.81
Min : Max	0.73 : 5.15	2.31 : 16.11	0.73 : 16.11	0.62 : 4.69	0.21 : 7.98	0.21 : 7.98
Change from Baseline						
n	7	4	11	12	35	47
Mean (SD)	-3.716 (2.2975)	-1.525 (5.5457)	-2.919 (3.6899)	-3.746 (3.1731)	-3.229 (3.7985)	-3.361 (3.6228)
Median	-4.560	-3.910	-4.560	-2.860	-2.040	-2.150
Q1 : Q3	-5.44 : -1.09	-4.82 : 1.77	-4.99 : -1.09	-3.95 : -1.87	-4.87 : -1.27	-4.53 : -1.45
Min : Max	-6.47 : -0.28	-4.99 : 6.71	-6.47 : 6.71	-10.98 : -0.29	-15.51 : 4.58	-15.51 : 4.58
Percent Change from Baseline						
n	7	4	11	12	35	47
Mean (SD)	-50.08 (18.894)	-21.25 (62.012)	-39.60 (39.741)	-60.44 (18.025)	-34.53 (65.576)	-41.14 (58.194)
Median	-50.61	-49.23	-50.61	-65.61	-51.00	-53.29
Q1 : Q3	-65.9 : -30.0	-55.9 : 13.4	-60.1 : -30.0	-70.4 : -55.1	-65.8 : -35.0	-69.7 : -36.6
Min : Max	-77.6 : -27.7	-57.9 : 71.4	-77.6 : 71.4	-79.5 : -10.2	-90.4 : 248.9	-90.4 : 248.9

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8100_ldlsi_sum_neg.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.51 Calculated LDL-C Over Time (On-treatment estimand) in SI Units - Raw Data Description: Subgroup Analysis According to Receptor-negative Mutation in Both LDLR or LDLRAP1 Alleles
Open-label Safety Analysis Set - OLTP

	Negative/Negative			Not Negative/Negative		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mmol/L)	DB Placebo IV Q4W (N=7)	Q4W (N=5)	Total (N=12)	DB Placebo IV Q4W (N=13)	Q4W (N=39)	Total (N=52)
Week 48						
Value						
n	5	4	9	11	38	49
Mean (SD)	3.848 (2.2463)	5.150 (2.6932)	4.427 (2.3904)	2.299 (1.9020)	3.003 (1.9144)	2.845 (1.9148)
Median	4.480	5.065	4.480	1.920	2.835	2.380
Q1 : Q3	2.33 : 4.82	2.87 : 7.44	2.49 : 6.68	1.32 : 2.31	1.63 : 3.52	1.58 : 3.29
Min : Max	0.93 : 6.68	2.49 : 7.98	0.93 : 7.98	0.36 : 6.92	0.65 : 10.13	0.36 : 10.13
Change from Baseline						
n	5	4	9	11	38	49
Mean (SD)	-3.782 (2.2132)	-3.525 (1.7035)	-3.668 (1.8857)	-3.744 (2.8389)	-3.358 (3.3514)	-3.445 (3.2192)
Median	-4.190	-3.660	-4.190	-2.740	-2.215	-2.360
Q1 : Q3	-5.42 : -1.71	-4.84 : -2.21	-5.36 : -1.71	-5.62 : -1.48	-4.79 : -1.22	-4.87 : -1.42
Min : Max	-6.29 : -1.30	-5.36 : -1.42	-6.29 : -1.30	-8.75 : -0.54	-13.36 : 1.99	-13.36 : 1.99
Percent Change from Baseline						
n	5	4	9	11	38	49
Mean (SD)	-49.29 (24.540)	-42.65 (20.869)	-46.34 (21.833)	-58.75 (22.036)	-42.71 (41.685)	-46.31 (38.553)
Median	-46.50	-46.59	-46.50	-55.84	-52.51	-54.26
Q1 : Q3	-58.4 : -35.8	-58.5 : -26.8	-58.4 : -35.8	-65.9 : -50.6	-66.5 : -33.6	-65.9 : -34.3
Min : Max	-85.4 : -20.4	-62.3 : -15.1	-85.4 : -15.1	-93.5 : -18.9	-83.3 : 117.6	-93.5 : 117.6

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8100_ldlsi_sum_neg.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.51 Calculated LDL-C Over Time (On-treatment estimand) in SI Units - Raw Data Description: Subgroup Analysis According to Receptor-negative Mutation in Both LDLR or LDLRAP1 Alleles
Open-label Safety Analysis Set - OLTP

	Negative/Negative			Not Negative/Negative		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mmol/L)	DB Placebo IV Q4W (N=7)	Q4W (N=5)	Total (N=12)	DB Placebo IV Q4W (N=13)	Q4W (N=39)	Total (N=52)
FU - W4						
Value						
n	0	1	1	0	3	3
Mean (SD)		2.360 (.)	2.360 (.)		3.953 (1.8224)	3.953 (1.8224)
Median		2.360	2.360		4.430	4.430
Q1 : Q3		2.36 : 2.36	2.36 : 2.36		1.94 : 5.49	1.94 : 5.49
Min : Max		2.36 : 2.36	2.36 : 2.36		1.94 : 5.49	1.94 : 5.49
Change from Baseline						
n	0	1	1	0	3	3
Mean (SD)		-3.130 (.)	-3.130 (.)		-2.357 (1.8194)	-2.357 (1.8194)
Median		-3.130	-3.130		-3.290	-3.290
Q1 : Q3		-3.13 : -3.13	-3.13 : -3.13		-3.52 : -0.26	-3.52 : -0.26
Min : Max		-3.13 : -3.13	-3.13 : -3.13		-3.52 : -0.26	-3.52 : -0.26
Percent Change from Baseline						
n	0	1	1	0	3	3
Mean (SD)		-57.01 (.)	-57.01 (.)		-35.83 (29.497)	-35.83 (29.497)
Median		-57.01	-57.01		-37.47	-37.47
Q1 : Q3		-57.0 : -57.0	-57.0 : -57.0		-64.5 : -5.5	-64.5 : -5.5
Min : Max		-57.0 : -57.0	-57.0 : -57.0		-64.5 : -5.5	-64.5 : -5.5

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8100_ldlsi_sum_neg.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.58 Calculated LDL-C Over Time (On-treatment estimand) in Conventional Units - Raw Data Description: Subgroup Analysis According to Japanese Patients
Open-label Safety Analysis Set - OLTP

	Japan			Rest of World		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mg/dL)	DB Placebo IV Q4W (N=4)	Q4W (N=6)	Total (N=10)	DB Placebo IV Q4W (N=16)	Q4W (N=38)	Total (N=54)
Baseline						
Value						
n	4	6	10	16	38	54
Mean (SD)	299.0 (133.16)	191.0 (23.11)	234.2 (96.53)	220.3 (146.62)	267.6 (182.01)	253.6 (172.30)
Median	336.0	194.5	209.5	187.0	204.5	197.5
Q1 : Q3	216 : 382	179 : 211	179 : 324	129 : 239	148 : 347	140 : 333
Min : Max	108 : 416	155 : 212	108 : 416	39 : 605	46 : 907	39 : 907
Week 28						
Value						
n	4	4	8	15	37	52
Mean (SD)	166.5 (74.34)	122.8 (48.37)	144.6 (62.60)	110.7 (73.56)	125.4 (84.67)	121.1 (81.19)
Median	188.5	116.5	152.5	90.0	107.0	103.5
Q1 : Q3	118 : 216	88 : 158	88 : 194	54 : 145	63 : 162	62 : 153
Min : Max	60 : 229	72 : 186	60 : 229	34 : 313	28 : 325	28 : 325
Change from Baseline						
n	4	4	8	15	37	52
Mean (SD)	-132.5 (80.01)	-65.5 (29.15)	-99.0 (66.26)	-114.3 (99.41)	-140.3 (132.70)	-132.8 (123.63)
Median	-120.5	-78.5	-82.0	-89.0	-109.0	-108.5
Q1 : Q3	-182 : -84	-82 : -49	-121 : -62	-191 : -41	-183 : -59	-187 : -57
Min : Max	-241 : -48	-83 : -22	-241 : -22	-293 : 45	-594 : 39	-594 : 45

Table 14.9.3.58 Calculated LDL-C Over Time (On-treatment estimand) in Conventional Units - Raw Data Description: Subgroup Analysis According to Japanese Patients
Open-label Safety Analysis Set - OLTP

	Japan			Rest of World		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mg/dL)	DB Placebo IV Q4W (N=4)	Q4W (N=6)	Total (N=10)	DB Placebo IV Q4W (N=16)	Q4W (N=38)	Total (N=54)
Week 28						
Percent Change from Baseline						
n	4	4	8	15	37	52
Mean (SD)	-43.56 (10.487)	-36.24 (18.271)	-39.90 (14.335)	-43.40 (30.773)	-45.80 (32.280)	-45.11 (31.570)
Median	-41.05	-40.42	-40.42	-49.72	-52.94	-51.33
Q1 : Q3	-51.2 : -35.9	-48.0 : -24.5	-49.0 : -35.9	-61.1 : -30.6	-67.3 : -39.4	-65.5 : -36.6
Min : Max	-57.9 : -34.2	-53.5 : -10.6	-57.9 : -10.6	-83.2 : 40.9	-92.4 : 56.5	-92.4 : 56.5
Week 32						
Value						
n	4	6	10	15	36	51
Mean (SD)	153.5 (68.88)	114.0 (36.61)	129.8 (52.37)	95.3 (45.56)	126.4 (84.06)	117.3 (75.72)
Median	171.0	99.5	122.0	88.0	109.5	102.0
Q1 : Q3	102 : 205	91 : 144	91 : 173	65 : 117	60 : 166	60 : 152
Min : Max	60 : 212	77 : 173	60 : 212	33 : 180	18 : 319	18 : 319
Change from Baseline						
n	4	6	10	15	36	51
Mean (SD)	-145.5 (94.25)	-77.0 (36.41)	-104.4 (70.35)	-125.8 (130.19)	-144.3 (139.42)	-138.9 (135.74)
Median	-131.0	-80.0	-97.0	-101.0	-115.5	-107.0
Q1 : Q3	-211 : -80	-112 : -35	-120 : -48	-202 : -52	-209 : -54	-205 : -52
Min : Max	-272 : -48	-120 : -35	-272 : -35	-453 : 65	-588 : 65	-588 : 65

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8200_ldlcv_sum_jpn.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.58 Calculated LDL-C Over Time (On-treatment estimand) in Conventional Units - Raw Data Description: Subgroup Analysis According to Japanese Patients
Open-label Safety Analysis Set - OLTP

	Japan			Rest of World		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mg/dL)	DB Placebo IV Q4W (N=4)	Q4W (N=6)	Total (N=10)	DB Placebo IV Q4W (N=16)	Q4W (N=38)	Total (N=54)
Week 32						
Percent Change from Baseline						
n	4	6	10	15	36	51
Mean (SD)	-46.88 (13.092)	-40.28 (17.542)	-42.92 (15.481)	-45.76 (34.338)	-43.27 (44.910)	-44.00 (41.753)
Median	-43.77	-47.81	-44.87	-55.65	-55.57	-55.65
Q1 : Q3	-54.9 : -38.8	-52.8 : -19.6	-52.8 : -34.6	-64.2 : -33.9	-69.4 : -29.7	-69.0 : -30.8
Min : Max	-65.4 : -34.6	-56.9 : -16.8	-65.4 : -16.8	-84.1 : 59.1	-91.7 : 141.3	-91.7 : 141.3
Week 36						
Value						
n	4	5	9	14	37	51
Mean (SD)	169.0 (86.54)	113.4 (38.95)	138.1 (66.53)	93.7 (53.49)	130.2 (83.93)	120.2 (78.01)
Median	177.0	100.0	108.0	86.5	103.0	100.0
Q1 : Q3	112 : 226	96 : 108	96 : 181	70 : 105	65 : 162	65 : 155
Min : Max	56 : 266	82 : 181	56 : 266	33 : 238	38 : 347	33 : 347
Change from Baseline						
n	4	5	9	14	37	51
Mean (SD)	-130.0 (52.23)	-73.6 (28.46)	-98.7 (48.08)	-129.2 (115.54)	-135.5 (134.04)	-133.8 (128.12)
Median	-153.0	-81.0	-83.0	-85.5	-96.0	-95.0
Q1 : Q3	-159 : -101	-83 : -73	-150 : -73	-207 : -36	-195 : -45	-207 : -43
Min : Max	-162 : -52	-104 : -27	-162 : -27	-367 : -6	-560 : 62	-560 : 62

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8200_ldlcv_sum_jpn.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

VV-RIM-00102077-1.0 Approved - 24 May 2020 GMT-5:00

Table 14.9.3.58 Calculated LDL-C Over Time (On-treatment estimand) in Conventional Units - Raw Data Description: Subgroup Analysis According to Japanese Patients
Open-label Safety Analysis Set - OLTP

	Japan			Rest of World		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mg/dL)	DB Placebo IV Q4W (N=4)	Q4W (N=6)	Total (N=10)	DB Placebo IV Q4W (N=16)	Q4W (N=38)	Total (N=54)
Week 36						
Percent Change from Baseline						
n	4	5	9	14	37	51
Mean (SD)	-44.73 (5.828)	-40.05 (15.211)	-42.13 (11.598)	-49.93 (22.364)	-41.05 (41.054)	-43.49 (36.872)
Median	-47.35	-46.37	-46.55	-55.50	-45.81	-50.67
Q1 : Q3	-48.1 : -41.3	-47.1 : -44.8	-48.1 : -44.8	-67.6 : -30.8	-64.3 : -34.4	-67.0 : -33.3
Min : Max	-48.1 : -36.1	-49.1 : -13.0	-49.1 : -13.0	-84.5 : -10.0	-85.4 : 134.8	-85.4 : 134.8
Week 40						
Value						
n	4	6	10	15	35	50
Mean (SD)	164.3 (63.32)	106.0 (32.58)	129.3 (53.21)	93.1 (63.20)	134.5 (91.78)	122.1 (85.75)
Median	173.0	97.0	105.5	92.0	115.0	104.5
Q1 : Q3	125 : 204	83 : 112	83 : 170	48 : 106	69 : 157	61 : 125
Min : Max	79 : 232	79 : 168	79 : 232	21 : 283	32 : 408	21 : 408
Change from Baseline						
n	4	6	10	15	35	50
Mean (SD)	-134.8 (94.47)	-85.0 (33.32)	-104.9 (65.21)	-128.0 (109.75)	-139.6 (144.21)	-136.1 (133.79)
Median	-132.0	-79.0	-89.0	-110.0	-112.0	-111.0
Q1 : Q3	-209 : -61	-112 : -67	-133 : -67	-213 : -31	-207 : -49	-207 : -49
Min : Max	-246 : -29	-133 : -40	-246 : -29	-354 : -4	-564 : 142	-564 : 142

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8200_ldlcv_sum_jpn.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.58 Calculated LDL-C Over Time (On-treatment estimand) in Conventional Units - Raw Data Description: Subgroup Analysis According to Japanese Patients
Open-label Safety Analysis Set - OLTP

	Japan			Rest of World		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mg/dL)	DB Placebo IV Q4W (N=4)	Q4W (N=6)	Total (N=10)	DB Placebo IV Q4W (N=16)	Q4W (N=38)	Total (N=54)
Week 40						
Percent Change from Baseline						
n	4	6	10	15	35	50
Mean (SD)	-40.95 (15.905)	-44.41 (14.883)	-43.02 (14.511)	-51.63 (24.703)	-40.12 (46.719)	-43.57 (41.440)
Median	-38.91	-46.98	-46.98	-56.41	-51.68	-53.53
Q1 : Q3	-54.3 : -27.6	-53.1 : -37.4	-53.1 : -28.4	-67.7 : -36.7	-68.2 : -35.6	-67.7 : -35.7
Min : Max	-59.1 : -26.9	-62.7 : -19.2	-62.7 : -19.2	-86.9 : -3.6	-82.9 : 150.0	-86.9 : 150.0
Week 44						
Value						
n	4	6	10	15	33	48
Mean (SD)	147.3 (65.10)	114.3 (43.23)	127.5 (52.34)	78.9 (42.60)	145.2 (115.16)	124.5 (102.63)
Median	169.0	104.0	111.0	68.0	116.0	97.0
Q1 : Q3	109 : 186	89 : 115	89 : 172	54 : 99	66 : 193	60 : 165
Min : Max	52 : 199	76 : 198	52 : 199	24 : 181	8 : 622	8 : 622
Change from Baseline						
n	4	6	10	15	33	48
Mean (SD)	-151.8 (81.90)	-76.7 (39.69)	-106.7 (67.93)	-142.1 (117.12)	-125.5 (164.37)	-130.7 (150.14)
Median	-150.5	-76.5	-94.5	-114.0	-83.0	-106.0
Q1 : Q3	-213 : -91	-110 : -64	-125 : -64	-190 : -67	-193 : -49	-192 : -52
Min : Max	-250 : -56	-123 : -10	-250 : -10	-424 : -11	-599 : 259	-599 : 259

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8200_ldlcv_sum_jpn.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

VV-RIM-00102077-1.0 Approved - 24 May 2020 GMT-5:00

Table 14.9.3.58 Calculated LDL-C Over Time (On-treatment estimand) in Conventional Units - Raw Data Description: Subgroup Analysis According to Japanese Patients
Open-label Safety Analysis Set - OLTP

	Japan			Rest of World		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mg/dL)	DB Placebo IV Q4W (N=4)	Q4W (N=6)	Total (N=10)	DB Placebo IV Q4W (N=16)	Q4W (N=38)	Total (N=54)
Week 44						
Percent Change from Baseline						
n	4	6	10	15	33	48
Mean (SD)	-50.28 (8.866)	-40.43 (19.227)	-44.37 (16.045)	-58.31 (20.242)	-31.87 (69.866)	-40.14 (59.990)
Median	-51.21	-45.93	-50.77	-65.83	-52.10	-56.98
Q1 : Q3	-56.0 : -44.6	-52.1 : -35.8	-52.1 : -38.6	-70.8 : -51.3	-65.9 : -35.1	-69.8 : -35.8
Min : Max	-60.1 : -38.6	-58.0 : -4.8	-60.1 : -4.8	-79.5 : -10.0	-90.5 : 249.3	-90.5 : 249.3
Week 48						
Value						
n	4	6	10	12	36	48
Mean (SD)	167.0 (85.90)	115.8 (34.63)	136.3 (61.83)	87.6 (70.86)	125.2 (84.99)	115.8 (82.61)
Median	179.5	109.5	119.0	76.0	113.0	91.0
Q1 : Q3	112 : 222	96 : 119	96 : 180	49 : 90	59 : 145	58 : 139
Min : Max	51 : 258	81 : 180	51 : 258	14 : 267	25 : 391	14 : 391
Change from Baseline						
n	4	6	10	12	36	48
Mean (SD)	-132.0 (87.94)	-75.2 (33.41)	-97.9 (63.71)	-149.3 (106.70)	-139.5 (131.58)	-141.9 (124.81)
Median	-114.0	-68.0	-70.0	-112.0	-92.5	-105.0
Q1 : Q3	-203 : -62	-111 : -60	-116 : -60	-213 : -63	-205 : -51	-208 : -53
Min : Max	-243 : -57	-116 : -28	-243 : -28	-338 : -21	-516 : 77	-516 : 77

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8200_ldlcv_sum_jpn.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.58 Calculated LDL-C Over Time (On-treatment estimand) in Conventional Units - Raw Data Description: Subgroup Analysis According to Japanese Patients
Open-label Safety Analysis Set - OLTP

	Japan			Rest of World		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mg/dL)	DB Placebo IV Q4W (N=4)	Q4W (N=6)	Total (N=10)	DB Placebo IV Q4W (N=16)	Q4W (N=38)	Total (N=54)
Week 48						
Percent Change from Baseline						
n	4	6	10	12	36	48
Mean (SD)	-44.53 (16.818)	-39.38 (15.572)	-41.44 (15.364)	-59.56 (23.421)	-43.25 (42.866)	-47.33 (39.340)
Median	-49.66	-41.00	-47.15	-59.45	-54.66	-55.35
Q1 : Q3	-55.6 : -33.5	-52.6 : -33.5	-52.8 : -33.5	-75.6 : -43.2	-68.3 : -35.2	-68.3 : -36.4
Min : Max	-58.4 : -20.4	-54.7 : -13.5	-58.4 : -13.5	-93.5 : -19.1	-83.3 : 117.4	-93.5 : 117.4
FU - W4						
Value						
n	0	3	3	0	1	1
Mean (SD)		112.3 (51.43)	112.3 (51.43)		212.0 (.)	212.0 (.)
Median		91.0	91.0		212.0	212.0
Q1 : Q3		75 : 171	75 : 171		212 : 212	212 : 212
Min : Max		75 : 171	75 : 171		212 : 212	212 : 212
Change from Baseline						
n	0	3	3	0	1	1
Mean (SD)		-89.0 (68.83)	-89.0 (68.83)		-127.0 (.)	-127.0 (.)
Median		-121.0	-121.0		-127.0	-127.0
Q1 : Q3		-136 : -10	-136 : -10		-127 : -127	-127 : -127
Min : Max		-136 : -10	-136 : -10		-127 : -127	-127 : -127

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8200_ldlcv_sum_jpn.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.58 Calculated LDL-C Over Time (On-treatment estimand) in Conventional Units - Raw Data Description: Subgroup Analysis According to Japanese Patients
Open-label Safety Analysis Set - OLTP

	Japan			Rest of World		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mg/dL)	DB Placebo IV Q4W (N=4)	Q4W (N=6)	Total (N=10)	DB Placebo IV Q4W (N=16)	Q4W (N=38)	Total (N=54)
FU - W4						
Percent Change from Baseline						
n	0	3	3	0	1	1
Mean (SD)		-42.35 (32.106)	-42.35 (32.106)		-37.46 (.)	-37.46 (.)
Median		-57.08	-57.08		-37.46	-37.46
Q1 : Q3		-64.5 : -5.5	-64.5 : -5.5		-37.5 : -37.5	-37.5 : -37.5
Min : Max		-64.5 : -5.5	-64.5 : -5.5		-37.5 : -37.5	-37.5 : -37.5

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8200_ldlcv_sum_jpn.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.59 Calculated LDL-C Over Time (On-treatment estimand) in SI Units - Raw Data Description: Subgroup Analysis According to Japanese Patients
Open-label Safety Analysis Set - OLTP

	Japan			Rest of World		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mmol/L)	DB Placebo IV Q4W (N=4)	Q4W (N=6)	Total (N=10)	DB Placebo IV Q4W (N=16)	Q4W (N=38)	Total (N=54)
Baseline						
Value						
n	4	6	10	16	38	54
Mean (SD)	7.743 (3.4458)	4.947 (0.5988)	6.065 (2.4983)	5.707 (3.7974)	6.930 (4.7140)	6.568 (4.4623)
Median	8.700	5.040	5.425	4.845	5.295	5.115
Q1 : Q3	5.60 : 9.89	4.64 : 5.46	4.64 : 8.39	3.33 : 6.18	3.83 : 8.99	3.63 : 8.62
Min : Max	2.80 : 10.77	4.01 : 5.49	2.80 : 10.77	1.01 : 15.67	1.19 : 23.49	1.01 : 23.49
Week 28						
Value						
n	4	4	8	15	37	52
Mean (SD)	4.310 (1.9267)	3.180 (1.2554)	3.745 (1.6221)	2.867 (1.9058)	3.247 (2.1932)	3.138 (2.1030)
Median	4.880	3.020	3.950	2.330	2.770	2.680
Q1 : Q3	3.04 : 5.58	2.27 : 4.10	2.27 : 5.03	1.40 : 3.76	1.63 : 4.20	1.59 : 3.96
Min : Max	1.55 : 5.93	1.86 : 4.82	1.55 : 5.93	0.88 : 8.11	0.73 : 8.42	0.73 : 8.42
Change from Baseline						
n	4	4	8	15	37	52
Mean (SD)	-3.433 (2.0691)	-1.695 (0.7537)	-2.564 (1.7149)	-2.961 (2.5742)	-3.633 (3.4368)	-3.439 (3.2017)
Median	-3.120	-2.030	-2.120	-2.310	-2.820	-2.810
Q1 : Q3	-4.70 : -2.17	-2.12 : -1.27	-3.12 : -1.61	-4.95 : -1.06	-4.74 : -1.53	-4.85 : -1.48
Min : Max	-6.24 : -1.25	-2.15 : -0.57	-6.24 : -0.57	-7.59 : 1.16	-15.38 : 1.01	-15.38 : 1.16

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8200_ldlsi_sum_jpn.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.59 Calculated LDL-C Over Time (On-treatment estimand) in SI Units - Raw Data Description: Subgroup Analysis According to Japanese Patients
Open-label Safety Analysis Set - OLTP

	Japan			Rest of World		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mmol/L)	DB Placebo IV Q4W (N=4)	Q4W (N=6)	Total (N=10)	DB Placebo IV Q4W (N=16)	Q4W (N=38)	Total (N=54)
Week 28						
Percent Change from Baseline						
n	4	4	8	15	37	52
Mean (SD)	-43.61 (10.497)	-36.23 (18.289)	-39.92 (14.357)	-43.42 (30.714)	-45.80 (32.258)	-45.11 (31.538)
Median	-41.15	-40.37	-40.37	-49.78	-52.92	-51.35
Q1 : Q3	-51.3 : -35.9	-48.0 : -24.4	-49.1 : -35.9	-61.1 : -30.5	-67.4 : -39.5	-65.5 : -36.5
Min : Max	-57.9 : -34.2	-53.6 : -10.6	-57.9 : -10.6	-83.2 : 40.7	-92.4 : 56.3	-92.4 : 56.3
Week 32						
Value						
n	4	6	10	15	36	51
Mean (SD)	3.975 (1.7860)	2.952 (0.9488)	3.361 (1.3574)	2.467 (1.1802)	3.275 (2.1774)	3.037 (1.9614)
Median	4.430	2.575	3.160	2.280	2.835	2.640
Q1 : Q3	2.64 : 5.31	2.36 : 3.73	2.36 : 4.48	1.68 : 3.03	1.54 : 4.29	1.55 : 3.94
Min : Max	1.55 : 5.49	1.99 : 4.48	1.55 : 5.49	0.85 : 4.66	0.47 : 8.26	0.47 : 8.26
Change from Baseline						
n	4	6	10	15	36	51
Mean (SD)	-3.768 (2.4367)	-1.995 (0.9395)	-2.704 (1.8186)	-3.259 (3.3709)	-3.738 (3.6115)	-3.597 (3.5157)
Median	-3.390	-2.075	-2.515	-2.610	-2.990	-2.780
Q1 : Q3	-5.46 : -2.08	-2.90 : -0.91	-3.10 : -1.25	-5.23 : -1.35	-5.40 : -1.39	-5.31 : -1.35
Min : Max	-7.04 : -1.25	-3.10 : -0.91	-7.04 : -0.91	-11.73 : 1.68	-15.23 : 1.68	-15.23 : 1.68

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8200_ldlsi_sum_jpn.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.59 Calculated LDL-C Over Time (On-treatment estimand) in SI Units - Raw Data Description: Subgroup Analysis According to Japanese Patients
Open-label Safety Analysis Set - OLTP

	Japan			Rest of World		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mmol/L)	DB Placebo IV Q4W (N=4)	Q4W (N=6)	Total (N=10)	DB Placebo IV Q4W (N=16)	Q4W (N=38)	Total (N=54)
Week 32						
Percent Change from Baseline						
n	4	6	10	15	36	51
Mean (SD)	-46.91 (13.077)	-40.31 (17.506)	-42.95 (15.455)	-45.81 (34.276)	-43.27 (44.893)	-44.02 (41.726)
Median	-43.85	-47.89	-45.03	-55.70	-55.53	-55.70
Q1 : Q3	-55.0 : -38.8	-52.8 : -19.6	-52.8 : -34.6	-64.2 : -34.0	-69.5 : -29.8	-69.3 : -30.7
Min : Max	-65.4 : -34.6	-56.8 : -16.9	-65.4 : -16.9	-84.1 : 58.9	-91.7 : 141.2	-91.7 : 141.2
Week 36						
Value						
n	4	5	9	14	37	51
Mean (SD)	4.378 (2.2420)	2.938 (1.0099)	3.578 (1.7235)	2.426 (1.3851)	3.371 (2.1744)	3.111 (2.0210)
Median	4.585	2.590	2.800	2.240	2.670	2.590
Q1 : Q3	2.90 : 5.86	2.49 : 2.80	2.49 : 4.69	1.81 : 2.72	1.68 : 4.20	1.68 : 4.01
Min : Max	1.45 : 6.89	2.12 : 4.69	1.45 : 6.89	0.85 : 6.16	0.98 : 8.99	0.85 : 8.99
Change from Baseline						
n	4	5	9	14	37	51
Mean (SD)	-3.365 (1.3493)	-1.906 (0.7360)	-2.554 (1.2429)	-3.349 (2.9932)	-3.510 (3.4716)	-3.466 (3.3184)
Median	-3.960	-2.100	-2.150	-2.215	-2.480	-2.460
Q1 : Q3	-4.12 : -2.62	-2.15 : -1.89	-3.88 : -1.89	-5.37 : -0.93	-5.05 : -1.17	-5.37 : -1.12
Min : Max	-4.19 : -1.35	-2.69 : -0.70	-4.19 : -0.70	-9.51 : -0.16	-14.50 : 1.61	-14.50 : 1.61

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8200_ldlsi_sum_jpn.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.59 Calculated LDL-C Over Time (On-treatment estimand) in SI Units - Raw Data Description: Subgroup Analysis According to Japanese Patients
Open-label Safety Analysis Set - OLTP

	Japan			Rest of World		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mmol/L)	DB Placebo IV Q4W (N=4)	Q4W (N=6)	Total (N=10)	DB Placebo IV Q4W (N=16)	Q4W (N=38)	Total (N=54)
Week 36						
Percent Change from Baseline						
n	4	5	9	14	37	51
Mean (SD)	-44.72 (5.853)	-40.05 (15.203)	-42.13 (11.597)	-49.99 (22.303)	-41.07 (41.097)	-43.52 (36.899)
Median	-47.33	-46.34	-46.50	-55.49	-45.91	-50.64
Q1 : Q3	-48.2 : -41.3	-47.1 : -44.8	-48.2 : -44.8	-67.6 : -30.7	-64.3 : -34.3	-66.9 : -33.6
Min : Max	-48.2 : -36.0	-49.0 : -13.0	-49.0 : -13.0	-84.6 : -10.2	-85.4 : 135.3	-85.4 : 135.3
Week 40						
Value						
n	4	6	10	15	35	50
Mean (SD)	4.255 (1.6387)	2.745 (0.8429)	3.349 (1.3776)	2.409 (1.6378)	3.483 (2.3771)	3.161 (2.2214)
Median	4.480	2.510	2.730	2.380	2.980	2.705
Q1 : Q3	3.23 : 5.29	2.15 : 2.90	2.15 : 4.40	1.24 : 2.75	1.79 : 4.07	1.58 : 3.24
Min : Max	2.05 : 6.01	2.05 : 4.35	2.05 : 6.01	0.54 : 7.33	0.83 : 10.57	0.54 : 10.57
Change from Baseline						
n	4	6	10	15	35	50
Mean (SD)	-3.488 (2.4465)	-2.202 (0.8604)	-2.716 (1.6874)	-3.318 (2.8419)	-3.615 (3.7353)	-3.526 (3.4652)
Median	-3.415	-2.045	-2.305	-2.850	-2.900	-2.875
Q1 : Q3	-5.41 : -1.57	-2.90 : -1.74	-3.44 : -1.74	-5.52 : -0.81	-5.36 : -1.27	-5.36 : -1.27
Min : Max	-6.37 : -0.75	-3.44 : -1.04	-6.37 : -0.75	-9.17 : -0.10	-14.61 : 3.68	-14.61 : 3.68

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8200_ldlsi_sum_jpn.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

VV-RIM-00102077-1.0 Approved - 24 May 2020 GMT-5:00

Table 14.9.3.59 Calculated LDL-C Over Time (On-treatment estimand) in SI Units - Raw Data Description: Subgroup Analysis According to Japanese Patients
Open-label Safety Analysis Set - OLTP

	Japan			Rest of World		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mmol/L)	DB Placebo IV Q4W (N=4)	Q4W (N=6)	Total (N=10)	DB Placebo IV Q4W (N=16)	Q4W (N=38)	Total (N=54)
Week 40						
Percent Change from Baseline						
n	4	6	10	15	35	50
Mean (SD)	-40.92 (15.930)	-44.42 (14.839)	-43.02 (14.498)	-51.70 (24.701)	-40.12 (46.759)	-43.59 (41.474)
Median	-38.88	-46.97	-46.97	-56.44	-51.81	-53.52
Q1 : Q3	-54.3 : -27.6	-53.1 : -37.5	-53.1 : -28.4	-67.7 : -36.8	-68.3 : -35.6	-67.7 : -35.8
Min : Max	-59.1 : -26.8	-62.7 : -19.3	-62.7 : -19.3	-86.9 : -3.5	-83.0 : 150.4	-86.9 : 150.4
Week 44						
Value						
n	4	6	10	15	33	48
Mean (SD)	3.813 (1.6829)	2.963 (1.1192)	3.303 (1.3536)	2.044 (1.1038)	3.762 (2.9823)	3.225 (2.6582)
Median	4.375	2.695	2.875	1.760	3.000	2.515
Q1 : Q3	2.83 : 4.80	2.31 : 2.98	2.31 : 4.45	1.40 : 2.56	1.71 : 5.00	1.56 : 4.26
Min : Max	1.35 : 5.15	1.97 : 5.13	1.35 : 5.15	0.62 : 4.69	0.21 : 16.11	0.21 : 16.11
Change from Baseline						
n	4	6	10	15	33	48
Mean (SD)	-3.930 (2.1194)	-1.983 (1.0245)	-2.762 (1.7581)	-3.683 (3.0327)	-3.248 (4.2569)	-3.384 (3.8883)
Median	-3.900	-1.980	-2.440	-2.950	-2.150	-2.740
Q1 : Q3	-5.52 : -2.35	-2.84 : -1.66	-3.24 : -1.66	-4.93 : -1.74	-4.99 : -1.27	-4.96 : -1.34
Min : Max	-6.47 : -1.45	-3.18 : -0.26	-6.47 : -0.26	-10.98 : -0.28	-15.51 : 6.71	-15.51 : 6.71

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8200_ldlsi_sum_jpn.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.59 Calculated LDL-C Over Time (On-treatment estimand) in SI Units - Raw Data Description: Subgroup Analysis According to Japanese Patients
Open-label Safety Analysis Set - OLTP

	Japan			Rest of World		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mmol/L)	DB Placebo IV Q4W (N=4)	Q4W (N=6)	Total (N=10)	DB Placebo IV Q4W (N=16)	Q4W (N=38)	Total (N=54)
Week 44						
Percent Change from Baseline						
n	4	6	10	15	33	48
Mean (SD)	-50.27 (8.838)	-40.39 (19.178)	-44.34 (16.013)	-58.32 (20.270)	-31.85 (69.859)	-40.12 (59.990)
Median	-51.20	-45.91	-50.74	-65.86	-51.95	-57.04
Q1 : Q3	-55.9 : -44.6	-52.0 : -35.8	-52.0 : -38.6	-70.8 : -51.4	-65.8 : -35.0	-69.8 : -35.8
Min : Max	-60.1 : -38.6	-57.9 : -4.8	-60.1 : -4.8	-79.5 : -10.2	-90.4 : 248.9	-90.4 : 248.9
Week 48						
Value						
n	4	6	10	12	36	48
Mean (SD)	4.325 (2.2245)	3.000 (0.8952)	3.530 (1.6009)	2.269 (1.8360)	3.242 (2.2022)	2.999 (2.1404)
Median	4.650	2.835	3.080	1.970	2.925	2.355
Q1 : Q3	2.90 : 5.75	2.49 : 3.08	2.49 : 4.66	1.26 : 2.32	1.53 : 3.76	1.50 : 3.60
Min : Max	1.32 : 6.68	2.10 : 4.66	1.32 : 6.68	0.36 : 6.92	0.65 : 10.13	0.36 : 10.13
Change from Baseline						
n	4	6	10	12	36	48
Mean (SD)	-3.418 (2.2743)	-1.947 (0.8610)	-2.535 (1.6471)	-3.868 (2.7645)	-3.612 (3.4076)	-3.676 (3.2324)
Median	-2.950	-1.760	-1.810	-2.900	-2.400	-2.715
Q1 : Q3	-5.24 : -1.60	-2.87 : -1.56	-3.00 : -1.56	-5.52 : -1.64	-5.30 : -1.32	-5.39 : -1.36
Min : Max	-6.29 : -1.48	-3.00 : -0.73	-6.29 : -0.73	-8.75 : -0.54	-13.36 : 1.99	-13.36 : 1.99

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8200_ldlsi_sum_jpn.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.59 Calculated LDL-C Over Time (On-treatment estimand) in SI Units - Raw Data Description: Subgroup Analysis According to Japanese Patients
Open-label Safety Analysis Set - OLTP

	Japan			Rest of World		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mmol/L)	DB Placebo IV Q4W (N=4)	Q4W (N=6)	Total (N=10)	DB Placebo IV Q4W (N=16)	Q4W (N=38)	Total (N=54)
Week 48						
Percent Change from Baseline						
n	4	6	10	12	36	48
Mean (SD)	-44.54 (16.821)	-39.39 (15.499)	-41.45 (15.325)	-59.55 (23.447)	-43.26 (42.868)	-47.33 (39.344)
Median	-49.68	-40.98	-47.07	-59.42	-54.65	-55.32
Q1 : Q3	-55.6 : -33.4	-52.6 : -33.6	-52.9 : -33.6	-75.7 : -43.2	-68.3 : -35.2	-68.3 : -36.5
Min : Max	-58.4 : -20.4	-54.6 : -13.5	-58.4 : -13.5	-93.5 : -18.9	-83.3 : 117.6	-93.5 : 117.6
FU - W4						
Value						
n	0	3	3	0	1	1
Mean (SD)		2.910 (1.3330)	2.910 (1.3330)		5.490 (.)	5.490 (.)
Median		2.360	2.360		5.490	5.490
Q1 : Q3		1.94 : 4.43	1.94 : 4.43		5.49 : 5.49	5.49 : 5.49
Min : Max		1.94 : 4.43	1.94 : 4.43		5.49 : 5.49	5.49 : 5.49
Change from Baseline						
n	0	3	3	0	1	1
Mean (SD)		-2.303 (1.7803)	-2.303 (1.7803)		-3.290 (.)	-3.290 (.)
Median		-3.130	-3.130		-3.290	-3.290
Q1 : Q3		-3.52 : -0.26	-3.52 : -0.26		-3.29 : -3.29	-3.29 : -3.29
Min : Max		-3.52 : -0.26	-3.52 : -0.26		-3.29 : -3.29	-3.29 : -3.29

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8200_ldlsi_sum_jpn.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.59 Calculated LDL-C Over Time (On-treatment estimand) in SI Units - Raw Data Description: Subgroup Analysis According to Japanese Patients
Open-label Safety Analysis Set - OLTP

	Japan			Rest of World		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mmol/L)	DB Placebo IV Q4W (N=4)	Q4W (N=6)	Total (N=10)	DB Placebo IV Q4W (N=16)	Q4W (N=38)	Total (N=54)
FU - W4						
Percent Change from Baseline						
n	0	3	3	0	1	1
Mean (SD)		-42.34 (32.085)	-42.34 (32.085)		-37.47 (.)	-37.47 (.)
Median		-57.01	-57.01		-37.47	-37.47
Q1 : Q3		-64.5 : -5.5	-64.5 : -5.5		-37.5 : -37.5	-37.5 : -37.5
Min : Max		-64.5 : -5.5	-64.5 : -5.5		-37.5 : -37.5	-37.5 : -37.5

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8200_ldlsi_sum_jpn.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.66 Calculated LDL-C Over Time (On-treatment estimand) - Raw Data Description (Conventional Units): Subgroup Analysis According to Apheresis Status
Open-label Safety Analysis Set - OLTP

	On Apheresis			Not On Apheresis		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mg/dL)	DB Placebo IV Q4W (N=8)	Q4W (N=14)	Total (N=22)	DB Placebo IV Q4W (N=12)	Q4W (N=30)	Total (N=42)
Baseline						
Value						
n	8	14	22	12	30	42
Mean (SD)	245.9 (119.67)	256.6 (99.79)	252.7 (104.72)	229.5 (163.47)	257.4 (197.34)	249.4 (186.75)
Median	257.0	211.5	211.5	190.5	188.5	188.5
Q1 : Q3	129 : 336	179 : 347	179 : 347	133 : 239	126 : 333	126 : 325
Min : Max	108 : 416	108 : 414	108 : 416	39 : 605	46 : 907	39 : 907
Week 28						
Value						
n	8	12	20	11	29	40
Mean (SD)	131.5 (63.22)	139.6 (52.59)	136.4 (55.59)	115.8 (85.48)	119.1 (90.86)	118.2 (88.34)
Median	115.5	140.0	127.0	90.0	91.0	90.5
Q1 : Q3	78 : 189	105 : 174	91 : 181	52 : 155	56 : 140	53 : 150
Min : Max	60 : 229	63 : 231	60 : 231	34 : 313	28 : 325	28 : 325
Change from Baseline						
n	8	12	20	11	29	40
Mean (SD)	-114.4 (74.67)	-127.0 (78.10)	-122.0 (75.00)	-120.9 (109.26)	-135.4 (145.03)	-131.5 (134.93)
Median	-117.5	-111.5	-117.5	-89.0	-84.0	-86.5
Q1 : Q3	-159 : -45	-183 : -74	-183 : -60	-191 : -62	-180 : -55	-186 : -57
Min : Max	-241 : -33	-294 : -22	-294 : -22	-293 : 45	-594 : 39	-594 : 45

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8300_ldlcv_sum_aph.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

VV-RIM-00102077-1.0 Approved - 24 May 2020 GMT-5:00

Table 14.9.3.66 Calculated LDL-C Over Time (On-treatment estimand) - Raw Data Description (Conventional Units): Subgroup Analysis According to Apheresis Status
Open-label Safety Analysis Set - OLTP

	On Apheresis			Not On Apheresis		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mg/dL)	DB Placebo IV Q4W (N=8)	Q4W (N=14)	Total (N=22)	DB Placebo IV Q4W (N=12)	Q4W (N=30)	Total (N=42)
Week 28						
Percent Change from Baseline						
n	8	12	20	11	29	40
Mean (SD)	-44.18 (13.945)	-45.26 (14.744)	-44.83 (14.064)	-42.89 (34.955)	-44.71 (36.080)	-44.21 (35.335)
Median	-41.05	-43.33	-43.33	-49.72	-56.76	-53.86
Q1 : Q3	-58.7 : -34.6	-54.2 : -40.6	-55.7 : -38.0	-64.7 : -30.6	-68.8 : -35.6	-68.0 : -34.6
Min : Max	-61.1 : -23.6	-73.3 : -10.6	-73.3 : -10.6	-83.2 : 40.9	-92.4 : 56.5	-92.4 : 56.5
Week 32						
Value						
n	8	14	22	11	28	39
Mean (SD)	122.0 (58.27)	136.9 (67.75)	131.5 (63.46)	97.0 (52.29)	118.5 (84.32)	112.5 (76.60)
Median	109.0	114.5	114.0	88.0	102.5	101.0
Q1 : Q3	72 : 171	91 : 157	82 : 157	51 : 152	57 : 163	55 : 152
Min : Max	60 : 212	77 : 314	60 : 314	33 : 180	18 : 319	18 : 319
Change from Baseline						
n	8	14	22	11	28	39
Mean (SD)	-123.9 (81.99)	-119.6 (77.99)	-121.2 (77.53)	-134.4 (147.51)	-142.3 (152.32)	-140.0 (149.08)
Median	-114.0	-104.5	-112.0	-101.0	-102.5	-101.0
Q1 : Q3	-176 : -50	-175 : -49	-175 : -49	-206 : -56	-209 : -53	-206 : -56
Min : Max	-272 : -39	-290 : -31	-290 : -31	-453 : 65	-588 : 65	-588 : 65

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8300_ldlcv_sum_aph.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.66 Calculated LDL-C Over Time (On-treatment estimand) - Raw Data Description (Conventional Units): Subgroup Analysis According to Apheresis Status
Open-label Safety Analysis Set - OLTP

	On Apheresis			Not On Apheresis		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mg/dL)	DB Placebo IV Q4W (N=8)	Q4W (N=14)	Total (N=22)	DB Placebo IV Q4W (N=12)	Q4W (N=30)	Total (N=42)
Week 32						
Percent Change from Baseline						
n	8	14	22	11	28	39
Mean (SD)	-47.83 (13.649)	-44.80 (18.287)	-45.90 (16.472)	-44.66 (39.591)	-41.86 (50.092)	-42.65 (46.872)
Median	-44.44	-51.58	-47.81	-55.65	-57.54	-56.30
Q1 : Q3	-61.4 : -38.8	-55.3 : -28.7	-56.9 : -34.6	-71.1 : -33.9	-70.1 : -29.4	-70.5 : -30.8
Min : Max	-65.4 : -27.9	-72.3 : -13.5	-72.3 : -13.5	-84.1 : 59.1	-91.7 : 141.3	-91.7 : 141.3
Week 36						
Value						
n	7	13	20	11	29	40
Mean (SD)	137.4 (73.13)	145.8 (67.19)	142.9 (67.51)	93.3 (60.71)	120.3 (84.70)	112.9 (79.02)
Median	105.0	124.0	116.0	74.0	102.0	91.0
Q1 : Q3	81 : 186	97 : 181	97 : 184	41 : 107	58 : 136	57 : 131
Min : Max	56 : 266	72 : 296	56 : 296	33 : 238	38 : 347	33 : 347
Change from Baseline						
n	7	13	20	11	29	40
Mean (SD)	-115.7 (73.64)	-114.3 (70.01)	-114.8 (69.35)	-138.1 (121.26)	-134.3 (146.94)	-135.4 (138.83)
Median	-150.0	-83.0	-91.5	-95.0	-86.0	-90.5
Q1 : Q3	-162 : -36	-176 : -73	-169 : -60	-207 : -73	-187 : -43	-197 : -44
Min : Max	-219 : -35	-239 : -27	-239 : -27	-367 : -6	-560 : 62	-560 : 62

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8300_ldlcv_sum_aph.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.66 Calculated LDL-C Over Time (On-treatment estimand) - Raw Data Description (Conventional Units): Subgroup Analysis According to Apheresis Status
Open-label Safety Analysis Set - OLTP

	On Apheresis			Not On Apheresis		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mg/dL)	DB Placebo IV Q4W (N=8)	Q4W (N=14)	Total (N=22)	DB Placebo IV Q4W (N=12)	Q4W (N=30)	Total (N=42)
Week 36						
Percent Change from Baseline						
n	7	13	20	11	29	40
Mean (SD)	-43.33 (14.403)	-42.78 (15.126)	-42.97 (14.494)	-52.23 (22.593)	-40.11 (45.825)	-43.44 (40.848)
Median	-46.55	-45.81	-46.09	-60.34	-51.19	-52.14
Q1 : Q3	-48.1 : -30.8	-49.1 : -33.3	-48.6 : -33.2	-67.6 : -44.2	-68.6 : -35.1	-68.1 : -37.2
Min : Max	-68.7 : -25.0	-64.3 : -13.0	-68.7 : -13.0	-84.5 : -10.0	-85.4 : 134.8	-85.4 : 134.8
Week 40						
Value						
n	8	14	22	11	27	38
Mean (SD)	132.4 (54.11)	127.5 (50.56)	129.3 (50.64)	90.4 (74.35)	131.8 (100.47)	119.8 (94.60)
Median	106.5	109.5	108.0	75.0	112.0	94.0
Q1 : Q3	95 : 173	99 : 125	99 : 168	33 : 106	55 : 157	54 : 132
Min : Max	79 : 232	79 : 251	79 : 251	21 : 283	32 : 408	21 : 408
Change from Baseline						
n	8	14	22	11	27	38
Mean (SD)	-113.5 (89.28)	-129.1 (81.46)	-123.4 (82.61)	-141.0 (116.72)	-132.9 (157.07)	-135.2 (145.03)
Median	-101.0	-112.0	-111.0	-119.0	-95.0	-99.0
Q1 : Q3	-194 : -30	-196 : -72	-196 : -67	-213 : -55	-204 : -39	-204 : -49
Min : Max	-246 : -13	-296 : -6	-296 : -6	-354 : -4	-564 : 142	-564 : 142

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8300_ldlcv_sum_aph.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.66 Calculated LDL-C Over Time (On-treatment estimand) - Raw Data Description (Conventional Units): Subgroup Analysis According to Apheresis Status
Open-label Safety Analysis Set - OLTP

	On Apheresis			Not On Apheresis		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mg/dL)	DB Placebo IV Q4W (N=8)	Q4W (N=14)	Total (N=22)	DB Placebo IV Q4W (N=12)	Q4W (N=30)	Total (N=42)
Week 40						
Percent Change from Baseline						
n	8	14	22	11	27	38
Mean (SD)	-40.11 (20.479)	-46.58 (18.864)	-44.23 (19.241)	-56.12 (23.535)	-37.72 (51.911)	-43.05 (45.987)
Median	-38.91	-47.43	-47.43	-58.26	-51.68	-53.53
Q1 : Q3	-57.8 : -24.5	-62.3 : -37.4	-61.3 : -28.4	-70.4 : -44.2	-69.2 : -35.6	-69.2 : -36.7
Min : Max	-67.4 : -11.1	-73.8 : -5.6	-73.8 : -5.6	-86.9 : -3.6	-82.9 : 150.0	-86.9 : 150.0
Week 44						
Value						
n	8	12	20	11	27	38
Mean (SD)	112.6 (61.63)	161.3 (153.66)	141.8 (125.16)	79.3 (45.95)	131.2 (81.18)	116.2 (75.97)
Median	103.5	111.0	108.0	61.0	110.0	95.0
Q1 : Q3	67 : 169	83 : 176	79 : 169	54 : 99	66 : 193	58 : 176
Min : Max	24 : 199	64 : 622	24 : 622	28 : 181	8 : 308	8 : 308
Change from Baseline						
n	8	12	20	11	27	38
Mean (SD)	-133.3 (73.39)	-84.0 (130.40)	-103.7 (111.54)	-152.1 (131.57)	-133.0 (161.42)	-138.6 (151.87)
Median	-119.5	-94.5	-112.0	-125.0	-83.0	-94.0
Q1 : Q3	-193 : -75	-151 : -54	-178 : -60	-190 : -67	-229 : -49	-193 : -54
Min : Max	-250 : -42	-281 : 259	-281 : 259	-424 : -11	-599 : 177	-599 : 177

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8300_ldlcv_sum_aph.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.66 Calculated LDL-C Over Time (On-treatment estimand) - Raw Data Description (Conventional Units): Subgroup Analysis According to Apheresis Status
Open-label Safety Analysis Set - OLTP

	On Apheresis			Not On Apheresis		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mg/dL)	DB Placebo IV Q4W (N=8)	Q4W (N=14)	Total (N=22)	DB Placebo IV Q4W (N=12)	Q4W (N=30)	Total (N=42)
Week 44						
Percent Change from Baseline						
n	8	12	20	11	27	38
Mean (SD)	-54.36 (15.472)	-37.13 (37.978)	-44.02 (31.594)	-58.27 (21.048)	-31.44 (73.976)	-39.20 (64.166)
Median	-55.16	-48.19	-51.41	-66.34	-52.10	-56.98
Q1 : Q3	-63.0 : -44.6	-56.0 : -38.2	-59.3 : -39.7	-70.8 : -51.3	-66.0 : -31.4	-69.8 : -35.1
Min : Max	-79.5 : -30.0	-70.1 : 71.3	-79.5 : 71.3	-77.6 : -10.0	-90.5 : 249.3	-90.5 : 249.3
Week 48						
Value						
n	7	13	20	9	29	38
Mean (SD)	132.1 (74.79)	136.3 (68.02)	134.9 (68.51)	88.2 (83.01)	118.2 (84.68)	111.1 (84.17)
Median	90.0	119.0	115.0	61.0	108.0	89.0
Q1 : Q3	78 : 186	96 : 136	90 : 177	36 : 89	51 : 142	48 : 142
Min : Max	51 : 258	68 : 308	51 : 308	14 : 267	25 : 391	14 : 391
Change from Baseline						
n	7	13	20	9	29	38
Mean (SD)	-103.3 (74.70)	-116.8 (80.22)	-112.1 (76.61)	-177.4 (108.52)	-136.3 (140.43)	-146.1 (133.36)
Median	-66.0	-87.0	-80.5	-188.0	-91.0	-107.0
Q1 : Q3	-162 : -50	-177 : -60	-170 : -56	-217 : -104	-185 : -47	-209 : -55
Min : Max	-243 : -39	-290 : -28	-290 : -28	-338 : -21	-516 : 77	-516 : 77

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8300_ldlcv_sum_aph.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.66 Calculated LDL-C Over Time (On-treatment estimand) - Raw Data Description (Conventional Units): Subgroup Analysis According to Apheresis Status
Open-label Safety Analysis Set - OLTP

	On Apheresis			Not On Apheresis		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mg/dL)	DB Placebo IV Q4W (N=8)	Q4W (N=14)	Total (N=22)	DB Placebo IV Q4W (N=12)	Q4W (N=30)	Total (N=42)
Week 48						
Percent Change from Baseline						
n	7	13	20	9	29	38
Mean (SD)	-43.07 (13.744)	-44.26 (17.474)	-43.84 (15.901)	-65.70 (23.482)	-42.00 (47.015)	-47.62 (43.546)
Median	-46.55	-47.74	-47.15	-64.81	-54.83	-57.02
Q1 : Q3	-54.4 : -33.3	-54.7 : -34.3	-54.5 : -33.9	-85.3 : -55.9	-70.0 : -33.3	-70.2 : -38.6
Min : Max	-58.4 : -20.4	-72.3 : -13.5	-72.3 : -13.5	-93.5 : -19.1	-83.3 : 117.4	-93.5 : 117.4
FU - W4						
Value						
n	0	3	3	0	1	1
Mean (SD)		112.3 (51.43)	112.3 (51.43)		212.0 (.)	212.0 (.)
Median		91.0	91.0		212.0	212.0
Q1 : Q3		75 : 171	75 : 171		212 : 212	212 : 212
Min : Max		75 : 171	75 : 171		212 : 212	212 : 212
Change from Baseline						
n	0	3	3	0	1	1
Mean (SD)		-89.0 (68.83)	-89.0 (68.83)		-127.0 (.)	-127.0 (.)
Median		-121.0	-121.0		-127.0	-127.0
Q1 : Q3		-136 : -10	-136 : -10		-127 : -127	-127 : -127
Min : Max		-136 : -10	-136 : -10		-127 : -127	-127 : -127

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8300_ldlcv_sum_aph.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.66 Calculated LDL-C Over Time (On-treatment estimand) - Raw Data Description (Conventional Units): Subgroup Analysis According to Apheresis Status
Open-label Safety Analysis Set - OLTP

	On Apheresis			Not On Apheresis		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mg/dL)	DB Placebo IV Q4W (N=8)	Q4W (N=14)	Total (N=22)	DB Placebo IV Q4W (N=12)	Q4W (N=30)	Total (N=42)
FU - W4						
Percent Change from Baseline						
n	0	3	3	0	1	1
Mean (SD)		-42.35 (32.106)	-42.35 (32.106)		-37.46 (.)	-37.46 (.)
Median		-57.08	-57.08		-37.46	-37.46
Q1 : Q3		-64.5 : -5.5	-64.5 : -5.5		-37.5 : -37.5	-37.5 : -37.5
Min : Max		-64.5 : -5.5	-64.5 : -5.5		-37.5 : -37.5	-37.5 : -37.5

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8300_ldlcv_sum_aph.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.67 Calculated LDL-C Over Time (On-treatment estimand) - Raw Data Description (SI Units): Subgroup Analysis According to Apheresis Status
Open-label Safety Analysis Set - OLTP

| | On Apheresis | | | Not On Apheresis | | |
| | DB Evinacumab 15 mg/kg IV | | | DB Evinacumab 15 mg/kg IV | | |
Calculated LDL-C (mmol/L)	DB Placebo IV Q4W (N=8)	Q4W (N=14)	Total (N=22)	DB Placebo IV Q4W (N=12)	Q4W (N=30)	Total (N=42)
Baseline						
Value						
n	8	14	22	12	30	42
Mean (SD)	6.368 (3.0968)	6.646 (2.5843)	6.545 (2.7111)	5.945 (4.2340)	6.666 (5.1110)	6.460 (4.8369)
Median	6.655	5.475	5.475	4.935	4.880	4.880
Q1 : Q3	3.33 : 8.70	4.64 : 8.99	4.64 : 8.99	3.44 : 6.18	3.26 : 8.62	3.26 : 8.42
Min : Max	2.80 : 10.77	2.80 : 10.72	2.80 : 10.77	1.01 : 15.67	1.19 : 23.49	1.01 : 23.49
Week 28						
Value						
n	8	12	20	11	29	40
Mean (SD)	3.405 (1.6366)	3.616 (1.3624)	3.532 (1.4397)	3.000 (2.2149)	3.086 (2.3536)	3.062 (2.2883)
Median	2.990	3.630	3.290	2.330	2.360	2.345
Q1 : Q3	2.01 : 4.88	2.72 : 4.51	2.36 : 4.68	1.35 : 4.01	1.45 : 3.63	1.38 : 3.89
Min : Max	1.55 : 5.93	1.63 : 5.98	1.55 : 5.98	0.88 : 8.11	0.73 : 8.42	0.73 : 8.42
Change from Baseline						
n	8	12	20	11	29	40
Mean (SD)	-2.963 (1.9319)	-3.289 (2.0236)	-3.159 (1.9423)	-3.132 (2.8294)	-3.508 (3.7561)	-3.405 (3.4944)
Median	-3.040	-2.885	-3.040	-2.310	-2.170	-2.240
Q1 : Q3	-4.11 : -1.16	-4.73 : -1.91	-4.73 : -1.55	-4.95 : -1.60	-4.66 : -1.43	-4.81 : -1.48
Min : Max	-6.24 : -0.86	-7.62 : -0.57	-7.62 : -0.57	-7.59 : 1.16	-15.38 : 1.01	-15.38 : 1.16

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8300_ldlsi_sum_aph.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.67 Calculated LDL-C Over Time (On-treatment estimand) - Raw Data Description (SI Units): Subgroup Analysis According to Apheresis Status
Open-label Safety Analysis Set - OLTP

Calculated LDL-C (mmol/L)	On Apheresis			Not On Apheresis		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
	DB Placebo IV Q4W (N=8)	Q4W (N=14)	Total (N=22)	DB Placebo IV Q4W (N=12)	Q4W (N=30)	Total (N=42)
Week 28						
Percent Change from Baseline						
n	8	12	20	11	29	40
Mean (SD)	-44.21 (13.916)	-45.26 (14.752)	-44.84 (14.058)	-42.91 (34.891)	-44.71 (36.055)	-44.21 (35.300)
Median	-41.15	-43.34	-43.34	-49.78	-56.66	-53.81
Q1 : Q3	-58.7 : -34.6	-54.2 : -40.6	-55.6 : -38.0	-64.7 : -30.5	-68.8 : -35.6	-68.1 : -34.6
Min : Max	-61.1 : -23.7	-73.3 : -10.6	-73.3 : -10.6	-83.2 : 40.7	-92.4 : 56.3	-92.4 : 56.3
Week 32						
Value						
n	8	14	22	11	28	39
Mean (SD)	3.160 (1.5099)	3.546 (1.7552)	3.405 (1.6441)	2.512 (1.3545)	3.070 (2.1843)	2.913 (1.9843)
Median	2.825	2.965	2.950	2.280	2.655	2.620
Q1 : Q3	1.87 : 4.43	2.36 : 4.07	2.12 : 4.07	1.32 : 3.94	1.46 : 4.23	1.42 : 3.94
Min : Max	1.55 : 5.49	1.99 : 8.13	1.55 : 8.13	0.85 : 4.66	0.47 : 8.26	0.47 : 8.26
Change from Baseline						
n	8	14	22	11	28	39
Mean (SD)	-3.208 (2.1206)	-3.100 (2.0192)	-3.139 (2.0065)	-3.482 (3.8195)	-3.684 (3.9457)	-3.627 (3.8613)
Median	-2.950	-2.710	-2.900	-2.610	-2.650	-2.610
Q1 : Q3	-4.56 : -1.30	-4.53 : -1.27	-4.53 : -1.27	-5.34 : -1.45	-5.40 : -1.38	-5.34 : -1.45
Min : Max	-7.04 : -1.01	-7.52 : -0.81	-7.52 : -0.81	-11.73 : 1.68	-15.23 : 1.68	-15.23 : 1.68

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8300_ldlsi_sum_aph.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.67 Calculated LDL-C Over Time (On-treatment estimand) - Raw Data Description (SI Units): Subgroup Analysis According to Apheresis Status
Open-label Safety Analysis Set - OLTP

	On Apheresis			Not On Apheresis		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mmol/L)	DB Placebo IV Q4W (N=8)	Q4W (N=14)	Total (N=22)	DB Placebo IV Q4W (N=12)	Q4W (N=30)	Total (N=42)
Week 32						
Percent Change from Baseline						
n	8	14	22	11	28	39
Mean (SD)	-47.84 (13.634)	-44.83 (18.259)	-45.93 (16.448)	-44.73 (39.521)	-41.85 (50.074)	-42.66 (46.843)
Median	-44.60	-51.60	-47.89	-55.70	-57.46	-56.17
Q1 : Q3	-61.4 : -38.8	-55.2 : -28.9	-56.8 : -34.6	-71.0 : -34.0	-70.2 : -29.3	-70.6 : -30.7
Min : Max	-65.4 : -27.8	-72.4 : -13.5	-72.4 : -13.5	-84.1 : 58.9	-91.7 : 141.2	-91.7 : 141.2
Week 36						
Value						
n	7	13	20	11	29	40
Mean (SD)	3.560 (1.8943)	3.775 (1.7411)	3.700 (1.7490)	2.414 (1.5722)	3.114 (2.1943)	2.922 (2.0472)
Median	2.720	3.210	3.005	1.920	2.640	2.355
Q1 : Q3	2.10 : 4.82	2.51 : 4.69	2.50 : 4.76	1.06 : 2.77	1.50 : 3.52	1.46 : 3.38
Min : Max	1.45 : 6.89	1.86 : 7.67	1.45 : 7.67	0.85 : 6.16	0.98 : 8.99	0.85 : 8.99
Change from Baseline						
n	7	13	20	11	29	40
Mean (SD)	-2.996 (1.9051)	-2.962 (1.8132)	-2.974 (1.7952)	-3.580 (3.1416)	-3.479 (3.8056)	-3.507 (3.5959)
Median	-3.880	-2.150	-2.370	-2.460	-2.220	-2.340
Q1 : Q3	-4.19 : -0.93	-4.56 : -1.89	-4.38 : -1.54	-5.37 : -1.89	-4.84 : -1.12	-5.11 : -1.15
Min : Max	-5.67 : -0.91	-6.19 : -0.70	-6.19 : -0.70	-9.51 : -0.16	-14.50 : 1.61	-14.50 : 1.61

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8300_ldlsi_sum_aph.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.67 Calculated LDL-C Over Time (On-treatment estimand) - Raw Data Description (SI Units): Subgroup Analysis According to Apheresis Status
Open-label Safety Analysis Set - OLTP

	On Apheresis			Not On Apheresis		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mmol/L)	DB Placebo IV Q4W (N=8)	Q4W (N=14)	Total (N=22)	DB Placebo IV Q4W (N=12)	Q4W (N=30)	Total (N=42)
Week 36						
Percent Change from Baseline						
n	7	13	20	11	29	40
Mean (SD)	-43.33 (14.402)	-42.80 (15.119)	-42.98 (14.489)	-52.32 (22.507)	-40.12 (45.874)	-43.47 (40.880)
Median	-46.50	-45.91	-46.12	-60.34	-51.38	-52.35
Q1 : Q3	-48.2 : -30.7	-49.0 : -33.6	-48.6 : -33.3	-67.6 : -44.3	-68.6 : -35.2	-68.1 : -37.2
Min : Max	-68.6 : -25.1	-64.3 : -13.0	-68.6 : -13.0	-84.6 : -10.2	-85.4 : 135.3	-85.4 : 135.3
Week 40						
Value						
n	8	14	22	11	27	38
Mean (SD)	3.428 (1.4020)	3.302 (1.3097)	3.348 (1.3118)	2.339 (1.9269)	3.413 (2.6022)	3.102 (2.4505)
Median	2.755	2.835	2.795	1.940	2.900	2.435
Q1 : Q3	2.45 : 4.48	2.56 : 3.24	2.56 : 4.35	0.85 : 2.75	1.42 : 4.07	1.40 : 3.42
Min : Max	2.05 : 6.01	2.05 : 6.50	2.05 : 6.50	0.54 : 7.33	0.83 : 10.57	0.54 : 10.57
Change from Baseline						
n	8	14	22	11	27	38
Mean (SD)	-2.940 (2.3107)	-3.344 (2.1090)	-3.197 (2.1384)	-3.655 (3.0228)	-3.442 (4.0686)	-3.503 (3.7565)
Median	-2.615	-2.900	-2.875	-3.090	-2.460	-2.560
Q1 : Q3	-5.01 : -0.78	-5.07 : -1.86	-5.07 : -1.74	-5.52 : -1.43	-5.29 : -1.01	-5.29 : -1.27
Min : Max	-6.37 : -0.34	-7.67 : -0.16	-7.67 : -0.16	-9.17 : -0.10	-14.61 : 3.68	-14.61 : 3.68

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8300_ldlsi_sum_aph.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.67 Calculated LDL-C Over Time (On-treatment estimand) - Raw Data Description (SI Units): Subgroup Analysis According to Apheresis Status
Open-label Safety Analysis Set - OLTP

	On Apheresis			Not On Apheresis		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mmol/L)	DB Placebo IV Q4W (N=8)	Q4W (N=14)	Total (N=22)	DB Placebo IV Q4W (N=12)	Q4W (N=30)	Total (N=42)
Week 40						
Percent Change from Baseline						
n	8	14	22	11	27	38
Mean (SD)	-40.14 (20.453)	-46.60 (18.822)	-44.25 (19.206)	-56.19 (23.556)	-37.71 (51.961)	-43.06 (46.036)
Median	-38.88	-47.42	-47.42	-58.39	-51.81	-53.52
Q1 : Q3	-57.8 : -24.5	-62.3 : -37.5	-61.3 : -28.4	-70.4 : -44.3	-69.2 : -35.6	-69.2 : -36.8
Min : Max	-67.4 : -11.2	-73.8 : -5.7	-73.8 : -5.7	-86.9 : -3.5	-83.0 : 150.4	-86.9 : 150.4
Week 44						
Value						
n	8	12	20	11	27	38
Mean (SD)	2.916 (1.5946)	4.178 (3.9790)	3.673 (3.2411)	2.053 (1.1907)	3.399 (2.1025)	3.009 (1.9679)
Median	2.680	2.875	2.795	1.580	2.850	2.460
Q1 : Q3	1.73 : 4.38	2.14 : 4.55	2.04 : 4.38	1.40 : 2.56	1.71 : 5.00	1.50 : 4.56
Min : Max	0.62 : 5.15	1.66 : 16.11	0.62 : 16.11	0.73 : 4.69	0.21 : 7.98	0.21 : 7.98
Change from Baseline						
n	8	12	20	11	27	38
Mean (SD)	-3.451 (1.8995)	-2.175 (3.3781)	-2.686 (2.8892)	-3.941 (3.4068)	-3.444 (4.1803)	-3.588 (3.9330)
Median	-3.095	-2.440	-2.895	-3.240	-2.150	-2.430
Q1 : Q3	-5.00 : -1.93	-3.91 : -1.40	-4.60 : -1.56	-4.93 : -1.74	-5.93 : -1.27	-4.99 : -1.40
Min : Max	-6.47 : -1.09	-7.28 : 6.71	-7.28 : 6.71	-10.98 : -0.28	-15.51 : 4.58	-15.51 : 4.58

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8300_ldlsi_sum_aph.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Protocol: R1500-CL-1629

Table 14.9.3.67 Calculated LDL-C Over Time (On-treatment estimand) - Raw Data Description (SI Units): Subgroup Analysis According to Apheresis Status
Open-label Safety Analysis Set - OLTP

	On Apheresis			Not On Apheresis		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mmol/L)	DB Placebo IV Q4W (N=8)	Q4W (N=14)	Total (N=22)	DB Placebo IV Q4W (N=12)	Q4W (N=30)	Total (N=42)
Week 44						
Percent Change from Baseline						
n	8	12	20	11	27	38
Mean (SD)	-54.37 (15.473)	-37.11 (37.973)	-44.01 (31.595)	-58.27 (21.082)	-31.41 (73.966)	-39.19 (64.163)
Median	-55.10	-48.15	-51.33	-66.35	-51.95	-57.04
Q1 : Q3	-63.0 : -44.6	-55.9 : -38.2	-59.2 : -39.7	-70.8 : -51.4	-66.0 : -31.4	-69.8 : -35.0
Min : Max	-79.5 : -30.0	-70.1 : 71.4	-79.5 : 71.4	-77.6 : -10.2	-90.4 : 248.9	-90.4 : 248.9
Week 48						
Value						
n	7	13	20	9	29	38
Mean (SD)	3.423 (1.9365)	3.530 (1.7626)	3.493 (1.7746)	2.286 (2.1509)	3.063 (2.1941)	2.879 (2.1808)
Median	2.330	3.080	2.975	1.580	2.800	2.310
Q1 : Q3	2.02 : 4.82	2.49 : 3.52	2.32 : 4.57	0.93 : 2.31	1.32 : 3.68	1.24 : 3.68
Min : Max	1.32 : 6.68	1.76 : 7.98	1.32 : 7.98	0.36 : 6.92	0.65 : 10.13	0.36 : 10.13
Change from Baseline						
n	7	13	20	9	29	38
Mean (SD)	-2.674 (1.9317)	-3.025 (2.0784)	-2.903 (1.9840)	-4.597 (2.8118)	-3.531 (3.6364)	-3.783 (3.4536)
Median	-1.710	-2.260	-2.085	-4.870	-2.360	-2.770
Q1 : Q3	-4.19 : -1.30	-4.58 : -1.56	-4.39 : -1.45	-5.62 : -2.69	-4.79 : -1.22	-5.42 : -1.42
Min : Max	-6.29 : -1.01	-7.52 : -0.73	-7.52 : -0.73	-8.75 : -0.54	-13.36 : 1.99	-13.36 : 1.99

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8300_ldlsi_sum_aph.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.67 Calculated LDL-C Over Time (On-treatment estimand) - Raw Data Description (SI Units): Subgroup Analysis According to Apheresis Status
Open-label Safety Analysis Set - OLTP

	On Apheresis			Not On Apheresis		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mmol/L)	DB Placebo IV Q4W (N=8)	Q4W (N=14)	Total (N=22)	DB Placebo IV Q4W (N=12)	Q4W (N=30)	Total (N=42)
Week 48						
Percent Change from Baseline						
n	7	13	20	9	29	38
Mean (SD)	-43.08 (13.724)	-44.27 (17.460)	-43.86 (15.886)	-65.69 (23.530)	-42.01 (47.016)	-47.61 (43.550)
Median	-46.50	-47.63	-47.07	-64.85	-54.79	-57.01
Q1 : Q3	-54.3 : -33.3	-54.6 : -34.3	-54.5 : -34.0	-85.4 : -55.8	-70.2 : -33.3	-70.2 : -38.5
Min : Max	-58.4 : -20.4	-72.4 : -13.5	-72.4 : -13.5	-93.5 : -18.9	-83.3 : 117.6	-93.5 : 117.6
FU - W4						
Value						
n	0	3	3	0	1	1
Mean (SD)		2.910 (1.3330)	2.910 (1.3330)		5.490 (.)	5.490 (.)
Median		2.360	2.360		5.490	5.490
Q1 : Q3		1.94 : 4.43	1.94 : 4.43		5.49 : 5.49	5.49 : 5.49
Min : Max		1.94 : 4.43	1.94 : 4.43		5.49 : 5.49	5.49 : 5.49
Change from Baseline						
n	0	3	3	0	1	1
Mean (SD)		-2.303 (1.7803)	-2.303 (1.7803)		-3.290 (.)	-3.290 (.)
Median		-3.130	-3.130		-3.290	-3.290
Q1 : Q3		-3.52 : -0.26	-3.52 : -0.26		-3.29 : -3.29	-3.29 : -3.29
Min : Max		-3.52 : -0.26	-3.52 : -0.26		-3.29 : -3.29	-3.29 : -3.29

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8300_ldlsi_sum_aph.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Table 14.9.3.67 Calculated LDL-C Over Time (On-treatment estimand) - Raw Data Description (SI Units): Subgroup Analysis According to Apheresis Status
Open-label Safety Analysis Set - OLTP

	On Apheresis			Not On Apheresis		
		DB Evinacumab 15 mg/kg IV			DB Evinacumab 15 mg/kg IV	
Calculated LDL-C (mmol/L)	DB Placebo IV Q4W (N=8)	Q4W (N=14)	Total (N=22)	DB Placebo IV Q4W (N=12)	Q4W (N=30)	Total (N=42)
FU - W4						
Percent Change from Baseline						
n	0	3	3	0	1	1
Mean (SD)		-42.34 (32.085)	-42.34 (32.085)		-37.47 (.)	-37.47 (.)
Median		-57.01	-57.01		-37.47	-37.47
Q1 : Q3		-64.5 : -5.5	-64.5 : -5.5		-37.5 : -37.5	-37.5 : -37.5
Min : Max		-64.5 : -5.5	-64.5 : -5.5		-37.5 : -37.5	-37.5 : -37.5

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/t_8300_ldlsi_sum_aph.sas (lei.yu 10APR2020 11:09 SAS Linux 9.4)

Protocol: R1500-CL-1719

Table 14.4.12 Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Demographic Characteristics
Safety Analysis Set

Demographic characteristics	New Evinacumab (N=46)	Continue Evinacumab (N=70)	Total (N=116)
Gender			
Male			
n	25	33	58
Mean (SD)	267.1 (124.59)	229.7 (132.69)	245.8 (129.50)
Median	263.0	198.0	209.5
Q1 : Q3	177.0 : 340.0	126.0 : 319.0	165.0 : 325.0
Min : Max	78 : 559	46 : 580	46 : 580
Female			
n	20	37	57
Mean (SD)	272.2 (121.25)	278.7 (214.57)	276.4 (186.00)
Median	268.0	195.0	222.0
Q1 : Q3	198.0 : 321.0	140.0 : 363.0	149.0 : 347.0
Min : Max	95 : 510	39 : 907	39 : 907
Age Category 1			
<18			
n	12	2	14
Mean (SD)	305.4 (93.00)	270.5 (184.55)	300.4 (100.49)
Median	303.5	270.5	303.5
Q1 : Q3	224.5 : 392.0	140.0 : 401.0	190.0 : 401.0
Min : Max	172 : 428	140 : 401	140 : 428

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Final/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_dem.sas (lei.yu 18SEP2023 12:52 SAS Linux 9.4)

Table 14.4.12 Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Demographic Characteristics
Safety Analysis Set

Demographic characteristics	New Evinacumab (N=46)	Continue Evinacumab (N=70)	Total (N=116)
Age Category 1			
>=18			
n	33	68	101
Mean (SD)	256.2 (129.40)	255.2 (182.37)	255.5 (166.25)
Median	254.0	197.5	208.0
Q1 : Q3	168.0 : 307.0	122.5 : 336.0	148.0 : 325.0
Min : Max	78 : 559	39 : 907	39 : 907
Age Category 2			
<65			
n	44	62	106
Mean (SD)	273.3 (120.18)	271.4 (185.71)	272.2 (161.10)
Median	270.5	206.5	235.5
Q1 : Q3	178.5 : 331.0	149.0 : 348.0	167.0 : 347.0
Min : Max	78 : 559	39 : 907	39 : 907
>=65			
n	1	8	9
Mean (SD)	95.0 (.)	133.1 (57.73)	128.9 (55.48)
Median	95.0	109.0	108.0
Q1 : Q3	95.0 : 95.0	87.5 : 194.5	91.0 : 181.0
Min : Max	95 : 95	71 : 212	71 : 212

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Final/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_dem.sas (lei.yu 18SEP2023 12:52 SAS Linux 9.4)

Table 14.4.12 Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Demographic Characteristics
Safety Analysis Set

Demographic characteristics	New Evinacumab (N=46)	Continue Evinacumab (N=70)	Total (N=116)
Race			
White			
n	30	49	79
Mean (SD)	261.6 (114.68)	248.0 (186.85)	253.2 (162.54)
Median	261.0	179.0	206.0
Q1 : Q3	177.0 : 320.0	117.0 : 333.0	133.0 : 325.0
Min : Max	78 : 510	46 : 907	46 : 907
Black or African American			
n	2	2	4
Mean (SD)	145.0 (48.08)	258.5 (246.78)	201.8 (159.26)
Median	145.0	258.5	145.0
Q1 : Q3	111.0 : 179.0	84.0 : 433.0	97.5 : 306.0
Min : Max	111 : 179	84 : 433	84 : 433
Asian			
n	3	9	12
Mean (SD)	255.7 (129.64)	224.2 (96.76)	232.1 (100.33)
Median	190.0	208.0	199.0
Q1 : Q3	172.0 : 405.0	179.0 : 212.0	175.5 : 280.0
Min : Max	172 : 405	108 : 416	108 : 416

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Final/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_dem.sas (lei.yu 18SEP2023 12:52 SAS Linux 9.4)

Regeneron Pharmaceuticals, Inc.
Protocol: R1500-CL-1719

Table 14.4.12 Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Demographic Characteristics
Safety Analysis Set

Demographic characteristics	New Evinacumab (N=46)	Continue Evinacumab (N=70)	Total (N=116)
Race			
Not Reported			
n	7	4	11
Mean (SD)	344.6 (132.35)	349.8 (36.03)	346.5 (104.43)
Median	283.0	339.5	332.0
Q1 : Q3	254.0 : 495.0	325.5 : 374.0	278.0 : 401.0
Min : Max	203 : 559	319 : 401	203 : 559
Other			
n	3	6	9
Mean (SD)	268.3 (168.62)	301.2 (278.44)	290.2 (236.29)
Median	285.0	227.5	260.0
Q1 : Q3	92.0 : 428.0	172.0 : 302.0	172.0 : 302.0
Min : Max	92 : 428	39 : 839	39 : 839
Ethnicity			
Hispanic or Latino			
n	2	4	6
Mean (SD)	101.5 (13.44)	453.3 (298.91)	336.0 (294.35)
Median	101.5	397.5	219.5
Q1 : Q3	92.0 : 111.0	219.5 : 687.0	111.0 : 535.0
Min : Max	92 : 111	179 : 839	92 : 839

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Final/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_dem.sas (lei.yu 18SEP2023 12:52 SAS Linux 9.4)

Table 14.4.12 Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Demographic Characteristics
Safety Analysis Set

Demographic characteristics	New Evinacumab (N=46)	Continue Evinacumab (N=70)	Total (N=116)
Ethnicity			
Not Hispanic or Latino			
n	36	63	99
Mean (SD)	264.1 (113.38)	238.1 (169.62)	247.5 (151.50)
Median	261.0	181.0	206.0
Q1 : Q3	177.5 : 321.0	117.0 : 325.0	148.0 : 322.0
Min : Max	78 : 510	39 : 907	39 : 907
Not Reported			
n	7	3	10
Mean (SD)	344.6 (132.35)	360.0 (36.29)	349.2 (109.66)
Median	283.0	347.0	336.0
Q1 : Q3	254.0 : 495.0	332.0 : 401.0	278.0 : 401.0
Min : Max	203 : 559	332 : 401	203 : 559
Region			
Japan			
n	2	9	11
Mean (SD)	181.0 (12.73)	224.2 (96.76)	216.4 (88.38)
Median	181.0	208.0	190.0
Q1 : Q3	172.0 : 190.0	179.0 : 212.0	172.0 : 212.0
Min : Max	172 : 190	108 : 416	108 : 416

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Final/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_dem.sas (lei.yu 18SEP2023 12:52 SAS Linux 9.4)

Table 14.4.12 Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Demographic Characteristics
Safety Analysis Set

Demographic characteristics	New Evinacumab (N=46)	Continue Evinacumab (N=70)	Total (N=116)
Region			
Rest of World			
n	43	61	104
Mean (SD)	273.5 (123.03)	260.3 (190.51)	265.7 (165.40)
Median	278.0	197.0	229.0
Q1 : Q3	178.0 : 340.0	119.0 : 339.0	148.5 : 339.5
Min : Max	78 : 559	39 : 907	39 : 907

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Final/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_dem.sas (lei.yu 18SEP2023 12:52 SAS Linux 9.4)

Table 14.4.13 Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Other Baseline Characteristics
Safety Analysis Set

	New Evinacumab (N=46)	Continue Evinacumab (N=70)	Total (N=116)
Baseline apheresis status according to Apheresis History (CRF)			
Yes			
n	22	23	45
Mean (SD)	298.5 (102.66)	289.4 (167.33)	293.8 (138.02)
Median	282.0	260.0	281.0
Q1 : Q3	217.0 : 340.0	179.0 : 363.0	181.0 : 348.0
Min : Max	161 : 559	108 : 839	108 : 839
No			
n	23	47	70
Mean (SD)	241.5 (133.90)	239.1 (186.94)	239.9 (170.34)
Median	203.0	179.0	186.5
Q1 : Q3	114.0 : 307.0	110.0 : 325.0	114.0 : 307.0
Min : Max	78 : 510	39 : 907	39 : 907

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Final/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_othbl.sas (lei.yu 18SEP2023 12:52 SAS Linux 9.4)

Page 60 of 4168

Protocol: R1500-CL-1719

Table 14.4.14 Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Baseline Calculated LDL-C
Safety Analysis Set

	New Evinacumab (N=46)	Continue Evinacumab (N=70)	Total (N=116)
Baseline Calculated LDL-C			
<130 mg/dL			
n	6	18	24
Mean (SD)	99.7 (13.81)	88.5 (27.53)	91.3 (25.02)
Median	101.5	87.5	93.5
Q1 : Q3	92.0 : 111.0	71.0 : 110.0	78.5 : 110.5
Min : Max	78 : 114	39 : 126	39 : 126
>=130 mg/dL			
n	39	52	91
Mean (SD)	295.5 (109.05)	313.5 (175.62)	305.8 (150.27)
Median	281.0	242.0	266.0
Q1 : Q3	203.0 : 366.0	179.5 : 407.5	183.0 : 379.0
Min : Max	133 : 559	140 : 907	133 : 907

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Final/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_ldlbl.sas (lei.yu 18SEP2023 12:52 SAS Linux 9.4)

Table 14.4.15 Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to HoFH Genotyping Safety Analysis Set

	New Evinacumab (N=46)	Continue Evinacumab (N=70)	Total (N=116)
HoFH Genotyping			
Homozygous			
n	22	33	55
Mean (SD)	320.1 (119.96)	286.0 (183.92)	299.6 (161.02)
Median	293.5	245.0	281.0
Q1 : Q3	255.0 : 379.0	172.0 : 347.0	180.0 : 363.0
Min : Max	92 : 559	39 : 907	39 : 907
Compound Heterozygous			
n	18	23	41
Mean (SD)	244.9 (104.33)	293.1 (195.62)	271.9 (162.05)
Median	230.0	202.0	206.0
Q1 : Q3	179.0 : 307.0	167.0 : 416.0	170.0 : 401.0
Min : Max	78 : 431	79 : 839	78 : 839
Double Heterozygous			
n	0	1	1
Mean (SD)		108.0 (.)	108.0 (.)
Median		108.0	108.0
Q1 : Q3		108.0 : 108.0	108.0 : 108.0
Min : Max		108 : 108	108 : 108

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Final/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_hofh.sas (lei.yu 18SEP2023 12:52 SAS Linux 9.4)

Table 14.4.15 Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to HoFH Genotyping
Safety Analysis Set

	New Evinacumab (N=46)	Continue Evinacumab (N=70)	Total (N=116)
HoFH Genotyping			
Other (Heterozygous, or unknown)			
n	4	12	16
Mean (SD)	124.5 (36.63)	123.5 (50.11)	123.8 (45.93)
Median	112.5	116.0	114.5
Q1 : Q3	103.0 : 146.0	87.5 : 161.5	93.0 : 161.5
Min : Max	95 : 178	46 : 211	46 : 211

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Final/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_hofh.sas (lei.yu 18SEP2023 12:52 SAS Linux 9.4)

Table 14.4.16 Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Receptor-negative Mutation in Both LDLR Alleles
Safety Analysis Set

	New Evinacumab (N=46)	Continue Evinacumab (N=70)	Total (N=116)
Receptor-negative Mutation in Both LDLR Alleles			
Receptor Negative/Negative			
n	8	11	19
Mean (SD)	384.5 (104.09)	349.5 (211.86)	364.3 (171.65)
Median	372.5	332.0	348.0
Q1 : Q3	284.0 : 461.5	195.0 : 433.0	283.0 : 433.0
Min : Max	281 : 559	39 : 839	39 : 839
Non Receptor Negative/Negative			
n	36	56	92
Mean (SD)	246.5 (112.37)	240.5 (175.04)	242.8 (152.92)
Median	240.0	179.5	200.0
Q1 : Q3	172.5 : 313.5	116.0 : 329.0	140.5 : 320.0
Min : Max	78 : 510	46 : 907	46 : 907

Note: Receptor-negative defined as a mutation resulting in termination codons, splice site mutations, frame shifts and large insertion/deletions.

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Final/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_recep.sas (lei.yu 18SEP2023 12:53 SAS Linux 9.4)

Table 14.4.17 Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Receptor-negative Mutation in Both LDLR or LDLRAP1 Alleles
Safety Analysis Set

	New Evinacumab (N=46)	Continue Evinacumab (N=70)	Total (N=116)
Receptor-negative Mutation in Both LDLR or LDLRAP1 Alleles			
Receptor Negative/Negative			
n	8	13	21
Mean (SD)	384.5 (104.09)	330.9 (198.78)	351.3 (167.96)
Median	372.5	319.0	332.0
Q1 : Q3	284.0 : 461.5	212.0 : 363.0	281.0 : 428.0
Min : Max	281 : 559	39 : 839	39 : 839
Non Receptor Negative/Negative			
n	36	56	92
Mean (SD)	246.5 (112.37)	240.5 (175.04)	242.8 (152.92)
Median	240.0	179.5	200.0
Q1 : Q3	172.5 : 313.5	116.0 : 329.0	140.5 : 320.0
Min : Max	78 : 510	46 : 907	46 : 907

Note: Receptor-negative defined as a mutation resulting in termination codons, splice site mutations, frame shifts and large insertion/deletions.

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Final/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_recap.sas (lei.yu 18SEP2023 12:52 SAS Linux 9.4)

Table 14.4.18 Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Null/Null Mutation in Both LDLR Alleles
Safety Analysis Set

	New Evinacumab (N=46)	Continue Evinacumab (N=70)	Total (N=116)
Null/Null Mutation in Both LDLR Alleles			
Null/Null			
n	13	23	36
Mean (SD)	365.5 (115.99)	354.3 (191.36)	358.3 (166.31)
Median	302.0	302.0	302.0
Q1 : Q3	281.0 : 495.0	197.0 : 505.0	232.5 : 501.0
Min : Max	226 : 559	148 : 839	148 : 839
Not Null/Null			
n	31	44	75
Mean (SD)	232.2 (103.02)	208.2 (161.07)	218.1 (139.71)
Median	206.0	171.0	179.0
Q1 : Q3	161.0 : 320.0	108.0 : 278.5	111.0 : 320.0
Min : Max	78 : 431	39 : 907	39 : 907

Note: Null/Null is defined as LDLR activity <=15%

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Final/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_nul.sas (lei.yu 18SEP2023 12:53 SAS Linux 9.4)

Table 14.4.19 Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Null/Null Mutation in Both LDLR or LDLRAP1
Alleles
Safety Analysis Set

	New Evinacumab (N=46)	Continue Evinacumab (N=70)	Total (N=116)
Null/Null Mutation in Both LDLR or LDLRAP1 Alleles			
Null/Null			
n	13	24	37
Mean (SD)	365.5 (115.99)	349.8 (188.48)	355.3 (165.04)
Median	302.0	284.0	302.0
Q1 : Q3	281.0 : 495.0	202.5 : 504.0	239.0 : 499.0
Min : Max	226 : 559	148 : 839	148 : 839
Not Null/Null			
n	31	45	76
Mean (SD)	232.2 (103.02)	208.3 (159.23)	218.1 (138.78)
Median	206.0	172.0	179.5
Q1 : Q3	161.0 : 320.0	108.0 : 232.0	112.5 : 313.5
Min : Max	78 : 431	39 : 907	39 : 907

Note: Null/Null is defined as LDLR activity <=15%

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Final/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_nulap.sas (lei.yu 18SEP2023 12:52 SAS Linux 9.4)

Table 14.4.20 Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Patients with Statin at Baseline
Safety Analysis Set

	New Evinacumab (N=46)	Continue Evinacumab (N=70)	Total (N=116)
Statin at Baseline			
Yes			
n	44	63	107
Mean (SD)	269.5 (123.15)	256.2 (182.04)	261.7 (159.93)
Median	268.5	197.0	212.0
Q1 : Q3	177.5 : 331.0	140.0 : 333.0	155.0 : 333.0
Min : Max	78 : 559	46 : 907	46 : 907
No			
n	1	7	8
Mean (SD)	263.0 (.)	250.7 (186.16)	252.3 (172.40)
Median	263.0	211.0	237.0
Q1 : Q3	263.0 : 263.0	91.0 : 416.0	103.0 : 382.0
Min : Max	263 : 263	39 : 535	39 : 535

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Final/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_stat.sas (lei.yu 18SEP2023 12:52 SAS Linux 9.4)

Table 14.4.21 Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Patients with PCSK9 Inhibitor at Baseline
Safety Analysis Set

	New Evinacumab (N=46)	Continue Evinacumab (N=70)	Total (N=116)
PCSK9 inhibitor at Baseline			
Yes			
n	21	50	71
Mean (SD)	256.7 (113.40)	246.7 (179.23)	249.7 (161.81)
Median	254.0	188.5	206.0
Q1 : Q3	190.0 : 307.0	117.0 : 333.0	133.0 : 325.0
Min : Max	78 : 499	39 : 907	39 : 907
No			
n	24	20	44
Mean (SD)	280.4 (130.00)	278.0 (188.45)	279.3 (157.27)
Median	281.0	210.0	279.5
Q1 : Q3	175.0 : 353.0	156.5 : 355.5	172.5 : 355.5
Min : Max	92 : 559	52 : 839	52 : 839

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Final/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_pcsk.sas (lei.yu 18SEP2023 12:53 SAS Linux 9.4)

Page 69 of 4168

VV-RIM-00307314-3.0 Approved - 21 Sep 2023 GMT-5:00

Table 14.4.22 Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Patients with Ezetimibe at Baseline
Safety Analysis Set

	New Evinacumab (N=46)	Continue Evinacumab (N=70)	Total (N=116)
Ezetimibe at Baseline			
Yes			
n	36	57	93
Mean (SD)	272.4 (126.84)	254.7 (166.78)	261.5 (152.08)
Median	257.0	197.0	212.0
Q1 : Q3	178.5 : 344.0	148.0 : 339.0	165.0 : 339.0
Min : Max	78 : 559	52 : 839	52 : 839
No			
n	9	13	22
Mean (SD)	257.1 (104.54)	259.8 (242.35)	258.7 (194.23)
Median	281.0	211.0	237.0
Q1 : Q3	177.0 : 320.0	84.0 : 325.0	114.0 : 325.0
Min : Max	111 : 421	39 : 907	39 : 907

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Final/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_eze.sas (lei.yu 18SEP2023 12:53 SAS Linux 9.4)

Table 14.4.23 Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Patients with Lomitapide at Baseline
Safety Analysis Set

	New Evinacumab (N=46)	Continue Evinacumab (N=70)	Total (N=116)
Lomitapide at Baseline			
Yes			
n	8	14	22
Mean (SD)	253.1 (143.75)	163.6 (57.01)	196.2 (104.12)
Median	194.5	175.5	182.0
Q1 : Q3	170.0 : 347.0	148.0 : 208.0	149.0 : 211.0
Min : Max	92 : 510	52 : 232	52 : 510
No			
n	37	56	93
Mean (SD)	272.9 (118.44)	278.6 (194.11)	276.3 (167.40)
Median	281.0	216.5	255.0
Q1 : Q3	179.0 : 322.0	122.5 : 382.0	155.0 : 348.0
Min : Max	78 : 559	39 : 907	39 : 907

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Final/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_lom.sas (lei.yu 18SEP2023 12:53 SAS Linux 9.4)

Table 14.4.12A Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Demographic Characteristics
Safety Analysis Set - Adolescents

Demographic characteristics	New Evinacumab (N=12)	Continue Evinacumab (N=2)	Total (N=14)
Gender			
Male			
n	8	1	9
Mean (SD)	292.4 (85.97)	401.0 (.)	304.4 (88.19)
Median	302.5	401.0	320.0
Q1 : Q3	219.0 : 359.5	401.0 : 401.0	259.0 : 379.0
Min : Max	172 : 405	401 : 401	172 : 405
Female			
n	4	1	5
Mean (SD)	331.5 (114.49)	140.0 (.)	293.2 (131.02)
Median	354.0	140.0	287.0
Q1 : Q3	238.5 : 424.5	140.0 : 140.0	190.0 : 421.0
Min : Max	190 : 428	140 : 140	140 : 428
Age Category 1			
<18			
n	12	2	14
Mean (SD)	305.4 (93.00)	270.5 (184.55)	300.4 (100.49)
Median	303.5	270.5	303.5
Q1 : Q3	224.5 : 392.0	140.0 : 401.0	190.0 : 401.0
Min : Max	172 : 428	140 : 401	140 : 428

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Final/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_dem.sas (lei.yu 18SEP2023 21:55 SAS Linux 9.4)

VV-RIM-00313764-2.0 Approved - 22 Sep 2023 GMT-5:00

Table 14.4.12A Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Demographic Characteristics
Safety Analysis Set - Adolescents

Demographic characteristics	New Evinacumab (N=12)	Continue Evinacumab (N=2)	Total (N=14)
Age Category 2			
<65			
n	12	2	14
Mean (SD)	305.4 (93.00)	270.5 (184.55)	300.4 (100.49)
Median	303.5	270.5	303.5
Q1 : Q3	224.5 : 392.0	140.0 : 401.0	190.0 : 401.0
Min : Max	172 : 428	140 : 401	140 : 428
Race			
White			
n	5	1	6
Mean (SD)	333.2 (66.37)	140.0 (.)	301.0 (98.72)
Median	320.0	140.0	303.5
Q1 : Q3	287.0 : 379.0	140.0 : 140.0	259.0 : 379.0
Min : Max	259 : 421	140 : 140	140 : 421
Black or African American			
n	1	0	1
Mean (SD)	179.0 (.)		179.0 (.)
Median	179.0		179.0
Q1 : Q3	179.0 : 179.0		179.0 : 179.0
Min : Max	179 : 179		179 : 179

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Final/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_dem.sas (lei.yu 18SEP2023 21:55 SAS Linux 9.4)

VV-RIM-00313764-2.0 Approved - 22 Sep 2023 GMT-5:00

Table 14.4.12A Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Demographic Characteristics
Safety Analysis Set - Adolescents

Demographic characteristics	New Evinacumab (N=12)	Continue Evinacumab (N=2)	Total (N=14)
Race			
Asian			
n	3	0	3
Mean (SD)	255.7 (129.64)		255.7 (129.64)
Median	190.0		190.0
Q1 : Q3	172.0 : 405.0		172.0 : 405.0
Min : Max	172 : 405		172 : 405
Not Reported			
n	1	1	2
Mean (SD)	340.0 (.)	401.0 (.)	370.5 (43.13)
Median	340.0	401.0	370.5
Q1 : Q3	340.0 : 340.0	401.0 : 401.0	340.0 : 401.0
Min : Max	340 : 340	401 : 401	340 : 401
Other			
n	2	0	2
Mean (SD)	356.5 (101.12)		356.5 (101.12)
Median	356.5		356.5
Q1 : Q3	285.0 : 428.0		285.0 : 428.0
Min : Max	285 : 428		285 : 428

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Final/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_dem.sas (lei.yu 18SEP2023 21:55 SAS Linux 9.4)

Table 14.4.12A Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Demographic Characteristics
Safety Analysis Set - Adolescents

Demographic characteristics	New Evinacumab (N=12)	Continue Evinacumab (N=2)	Total (N=14)
Ethnicity			
Not Hispanic or Latino			
n	11	1	12
Mean (SD)	302.3 (96.87)	140.0 (.)	288.8 (103.56)
Median	287.0	140.0	286.0
Q1 : Q3	190.0 : 405.0	140.0 : 140.0	184.5 : 392.0
Min : Max	172 : 428	140 : 140	140 : 428
Not Reported			
n	1	1	2
Mean (SD)	340.0 (.)	401.0 (.)	370.5 (43.13)
Median	340.0	401.0	370.5
Q1 : Q3	340.0 : 340.0	401.0 : 401.0	340.0 : 401.0
Min : Max	340 : 340	401 : 401	340 : 401
Region			
Japan			
n	2	0	2
Mean (SD)	181.0 (12.73)		181.0 (12.73)
Median	181.0		181.0
Q1 : Q3	172.0 : 190.0		172.0 : 190.0
Min : Max	172 : 190		172 : 190

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Final/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_dem.sas (lei.yu 18SEP2023 21:55 SAS Linux 9.4)

Table 14.4.12A Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Demographic Characteristics
Safety Analysis Set - Adolescents

Demographic characteristics	New Evinacumab (N=12)	Continue Evinacumab (N=2)	Total (N=14)
Region			
Rest of World			
n	10	2	12
Mean (SD)	330.3 (80.16)	270.5 (184.55)	320.3 (94.31)
Median	330.0	270.5	330.0
Q1 : Q3	285.0 : 405.0	140.0 : 401.0	272.0 : 403.0
Min : Max	179 : 428	140 : 401	140 : 428

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Final/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_dem.sas (lei.yu 18SEP2023 21:55 SAS Linux 9.4)

Table 14.4.13A Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Other Baseline Characteristics
Safety Analysis Set - Adolescents

	New Evinacumab (N=12)	Continue Evinacumab (N=2)	Total (N=14)
Baseline apheresis status according to Apheresis History (CRF)			
Yes			
n	7	2	9
Mean (SD)	300.4 (96.50)	270.5 (184.55)	293.8 (106.85)
Median	320.0	270.5	320.0
Q1 : Q3	179.0 : 379.0	140.0 : 401.0	179.0 : 379.0
Min : Max	172 : 428	140 : 401	140 : 428
No			
n	5	0	5
Mean (SD)	312.4 (98.55)		312.4 (98.55)
Median	287.0		287.0
Q1 : Q3	259.0 : 405.0		259.0 : 405.0
Min : Max	190 : 421		190 : 421

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Final/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_othbl.sas (lei.yu 18SEP2023 21:55 SAS Linux 9.4)

Page 54 of 3040

Table 14.4.14A Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Baseline Calculated LDL-C
Safety Analysis Set - Adolescents

	New Evinacumab (N=12)	Continue Evinacumab (N=2)	Total (N=14)
Baseline Calculated LDL-C			
>=130 mg/dL			
n	12	2	14
Mean (SD)	305.4 (93.00)	270.5 (184.55)	300.4 (100.49)
Median	303.5	270.5	303.5
Q1 : Q3	224.5 : 392.0	140.0 : 401.0	190.0 : 401.0
Min : Max	172 : 428	140 : 401	140 : 428

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Final/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_ldlbl.sas (lei.yu 18SEP2023 21:55 SAS Linux 9.4)

Table 14.4.15A Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to HoFH Genotyping Safety
Analysis Set - Adolescents

	New Evinacumab (N=12)	Continue Evinacumab (N=2)	Total (N=14)
HoFH Genotyping			
Homozygous			
n	5	1	6
Mean (SD)	350.4 (55.11)	140.0 (.)	315.3 (99.03)
Median	340.0	140.0	330.0
Q1 : Q3	320.0 : 379.0	140.0 : 140.0	285.0 : 379.0
Min : Max	285 : 428	140 : 140	140 : 428
Compound Heterozygous			
n	6	1	7
Mean (SD)	290.2 (103.61)	401.0 (.)	306.0 (103.45)
Median	273.0	401.0	287.0
Q1 : Q3	190.0 : 405.0	401.0 : 401.0	190.0 : 405.0
Min : Max	179 : 421	401 : 401	179 : 421

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Final/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_hofh.sas (lei.yu 18SEP2023 21:55 SAS Linux 9.4)

Table 14.4.16A Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Receptor-negative Mutation in Both LDLR Alleles
Safety Analysis Set - Adolescents

	New Evinacumab (N=12)	Continue Evinacumab (N=2)	Total (N=14)
Receptor-negative Mutation in Both LDLR Alleles			
Receptor Negative/Negative			
n	3	1	4
Mean (SD)	364.0 (72.67)	140.0 (.)	308.0 (126.75)
Median	379.0	140.0	332.0
Q1 : Q3	285.0 : 428.0	140.0 : 140.0	212.5 : 403.5
Min : Max	285 : 428	140 : 140	140 : 428
Non Receptor Negative/Negative			
n	8	1	9
Mean (SD)	300.1 (89.65)	401.0 (.)	311.3 (90.35)
Median	303.5	401.0	320.0
Q1 : Q3	224.5 : 372.5	401.0 : 401.0	259.0 : 401.0
Min : Max	179 : 421	401 : 401	179 : 421

Note: Receptor-negative defined as a mutation resulting in termination codons, splice site mutations, frame shifts and large insertion/deletions.

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Final/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_recep.sas (lei.yu 18SEP2023 21:55 SAS Linux 9.4)

Table 14.4.17A Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Receptor-negative Mutation in Both LDLR or
LDLRAP1 Alleles
Safety Analysis Set - Adolescents

	New Evinacumab (N=12)	Continue Evinacumab (N=2)	Total (N=14)
Receptor-negative Mutation in Both LDLR or LDLRAP1 Alleles			
Receptor Negative/Negative			
n	3	1	4
Mean (SD)	364.0 (72.67)	140.0 (.)	308.0 (126.75)
Median	379.0	140.0	332.0
Q1 : Q3	285.0 : 428.0	140.0 : 140.0	212.5 : 403.5
Min : Max	285 : 428	140 : 140	140 : 428
Non Receptor Negative/Negative			
n	8	1	9
Mean (SD)	300.1 (89.65)	401.0 (.)	311.3 (90.35)
Median	303.5	401.0	320.0
Q1 : Q3	224.5 : 372.5	401.0 : 401.0	259.0 : 401.0
Min : Max	179 : 421	401 : 401	179 : 421

Note: Receptor-negative defined as a mutation resulting in termination codons, splice site mutations, frame shifts and large insertion/deletions.

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Final/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_recap.sas (lei.yu 18SEP2023 21:55 SAS Linux 9.4)

VV-RIM-00313764-2.0 Approved - 22 Sep 2023 GMT-5:00

Table 14.4.18A Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Null/Null Mutation in Both LDLR Alleles
Safety Analysis Set - Adolescents

	New Evinacumab (N=12)	Continue Evinacumab (N=2)	Total (N=14)
Null/Null Mutation in Both LDLR Alleles			
Null/Null			
n	3	1	4
Mean (SD)	322.3 (86.59)	401.0 (.)	342.0 (80.90)
Median	287.0	401.0	344.0
Q1 : Q3	259.0 : 421.0	401.0 : 401.0	273.0 : 411.0
Min : Max	259 : 421	401 : 401	259 : 421
Not Null/Null			
n	8	1	9
Mean (SD)	315.8 (93.07)	140.0 (.)	296.2 (104.93)
Median	330.0	140.0	320.0
Q1 : Q3	237.5 : 392.0	140.0 : 140.0	190.0 : 379.0
Min : Max	179 : 428	140 : 140	140 : 428

Note: Null/Null is defined as LDLR activity <=15%

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Final/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_nul.sas (lei.yu 18SEP2023 21:55 SAS Linux 9.4)

Table 14.4.19A Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Null/Null Mutation in Both LDLR or LDLRAP1
Alleles
Safety Analysis Set - Adolescents

	New Evinacumab (N=12)	Continue Evinacumab (N=2)	Total (N=14)
Null/Null Mutation in Both LDLR or LDLRAP1 Alleles			
Null/Null			
n	3	1	4
Mean (SD)	322.3 (86.59)	401.0 (.)	342.0 (80.90)
Median	287.0	401.0	344.0
Q1 : Q3	259.0 : 421.0	401.0 : 401.0	273.0 : 411.0
Min : Max	259 : 421	401 : 401	259 : 421
Not Null/Null			
n	8	1	9
Mean (SD)	315.8 (93.07)	140.0 (.)	296.2 (104.93)
Median	330.0	140.0	320.0
Q1 : Q3	237.5 : 392.0	140.0 : 140.0	190.0 : 379.0
Min : Max	179 : 428	140 : 140	140 : 428

Note: Null/Null is defined as LDLR activity <=15%

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Final/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_nulap.sas (lei.yu 18SEP2023 21:55 SAS Linux 9.4)

Table 14.4.20A Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Patients with Statin at Baseline
Safety Analysis Set - Adolescents

	New Evinacumab (N=12)	Continue Evinacumab (N=2)	Total (N=14)
Statin at Baseline			
Yes			
n	12	2	14
Mean (SD)	305.4 (93.00)	270.5 (184.55)	300.4 (100.49)
Median	303.5	270.5	303.5
Q1 : Q3	224.5 : 392.0	140.0 : 401.0	190.0 : 401.0
Min : Max	172 : 428	140 : 401	140 : 428

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Final/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_stat.sas (lei.yu 18SEP2023 21:55 SAS Linux 9.4)

Table 14.4.21A Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Patients with PCSK9 Inhibitor at Baseline
Safety Analysis Set - Adolescents

	New Evinacumab (N=12)	Continue Evinacumab (N=2)	Total (N=14)
PCSK9 inhibitor at Baseline			
Yes			
n	5	1	6
Mean (SD)	312.4 (98.55)	401.0 (.)	327.2 (95.28)
Median	287.0	401.0	344.0
Q1 : Q3	259.0 : 405.0	401.0 : 401.0	259.0 : 405.0
Min : Max	190 : 421	401 : 401	190 : 421
No			
n	7	1	8
Mean (SD)	300.4 (96.50)	140.0 (.)	280.4 (105.83)
Median	320.0	140.0	302.5
Q1 : Q3	179.0 : 379.0	140.0 : 140.0	175.5 : 359.5
Min : Max	172 : 428	140 : 140	140 : 428

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Final/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_pcsk.sas (lei.yu 18SEP2023 21:55 SAS Linux 9.4)

VV-RIM-00313764-2.0 Approved - 22 Sep 2023 GMT-5:00

Table 14.4.22A Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Patients with Ezetimibe at Baseline
Safety Analysis Set - Adolescents

	New Evinacumab (N=12)	Continue Evinacumab (N=2)	Total (N=14)
Ezetimibe at Baseline			
Yes			
n	8	2	10
Mean (SD)	287.1 (105.12)	270.5 (184.55)	283.8 (111.48)
Median	272.0	270.5	272.0
Q1 : Q3	184.5 : 392.0	140.0 : 401.0	179.0 : 401.0
Min : Max	172 : 428	140 : 401	140 : 428
No			
n	4	0	4
Mean (SD)	342.0 (57.02)		342.0 (57.02)
Median	330.0		330.0
Q1 : Q3	303.5 : 380.5		303.5 : 380.5
Min : Max	287 : 421		287 : 421

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Final/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_eze.sas (lei.yu 18SEP2023 21:55 SAS Linux 9.4)

Table 14.4.23A Calculated LDL-C at Baseline - Quantitative Summary in Conventional Units : Subgroup Analysis According to Patients with Lomitapide at Baseline
Safety Analysis Set - Adolescents

	New Evinacumab (N=12)	Continue Evinacumab (N=2)	Total (N=14)
Lomitapide at Baseline			
Yes			
n	1	0	1
Mean (SD)	172.0 (.)		172.0 (.)
Median	172.0		172.0
Q1 : Q3	172.0 : 172.0		172.0 : 172.0
Min : Max	172 : 172		172 : 172
No			
n	11	2	13
Mean (SD)	317.5 (87.02)	270.5 (184.55)	310.3 (97.27)
Median	320.0	270.5	320.0
Q1 : Q3	259.0 : 405.0	140.0 : 401.0	259.0 : 401.0
Min : Max	179 : 428	140 : 401	140 : 428

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Final/Analysis_CSR/Programs/TFL/Generated/t_0120_ldl_bl_subgrp_lom.sas (lei.yu 18SEP2023 21:55 SAS Linux 9.4)